

U.S. SECURITIES AND EXCHANGE COMMISSION

FORM C COVER PAGE

Form C: Offering Statement

Form C-U: Progress Update

Form C/A: Amendment to Offering Statement

Check box if Amendment is material and investors must reconfirm within five business days.

Form C-AR: Annual Report

Form C-AR/A: Amendment to Annual Report

Form C-TR: Termination of Reporting

Name of issuer:

Care2Care International LLC

Legal status of issuer:

Form: Limited Liability Company

Jurisdiction of Incorporation/Organization: New Hampshire

Date of organization: February 20, 2021

Physical address of issuer:

70 Meadow Road, Portsmouth, NH 03801

Website of issuer:

www.care2careinternational.com

Name of intermediary through which the offering will be conducted:

TycoonInvest Portal LLC

CIK number of intermediary:

0001815196

SEC file number of intermediary:

007-00245

CRD number, if applicable, of intermediary:

310166

Amount of compensation to be paid to the intermediary, whether as a dollar amount or a percentage of the Offering amount, or a good faith estimate if the exact amount is not available at the time of the filing, for conducting the Offering, including the amount of referral and any other fees associated with the Offering

5.0% of the amount raised

Any other direct or indirect interest in the issuer held by the intermediary, or any arrangement for the intermediary to acquire such an interest

No

Name of qualified third party "Escrow Agent" which the Offering will utilize

Prime Trust LLC

Type of security offered

Convertible Promissory Notes

Target number of Securities to be offered

10,000

Price (or method for determining price)

\$1.00

Target offering amount

\$10,000.00

Oversubscriptions accepted:

Yes

No

If yes, disclose how oversubscriptions will be allocated:

Pro-rata basis

First-come, first-served basis

Other: At the issuer's discretion

Maximum offering amount (if different from target offering amount)

\$400,000.00

Deadline to reach the target offering amount

January 1, 2022

NOTE: If the sum of the investment commitments does not equal or exceed the target offering amount at the Offering deadline, no Securities will be sold in the Offering, investment commitments will be cancelled and committed funds will be returned.

	Period Ending 4/30/2021	Prior fiscal year-end
Total Assets	\$100.00	N/A
Cash & Cash Equivalents	\$100.00	N/A
Accounts Receivable	\$0.00	N/A
Short-term Debt	\$0.00	N/A
Long-term Debt	\$0.00	N/A
Revenues/Sales	\$0.00	N/A
Cost of Goods Sold	\$0.00	N/A
Taxes Paid	\$0.00	N/A
Net Income	\$0.00	N/A

The jurisdictions in which the issuer intends to offer the Securities:

Alabama, Alaska, Arizona, Arkansas, California, Colorado, Connecticut, New Hampshire, District Of Columbia, Florida, Georgia, Guam, Hawaii, Idaho, Illinois, Indiana, Iowa, Kansas, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Michigan, Minnesota, Mississippi, Missouri, Montana, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, Puerto Rico, Rhode Island, South Carolina, South Dakota, Tennessee, Texas, Utah, Vermont, Virgin Islands, U.S., Virginia, Washington, West Virginia, Wisconsin, Wyoming, American Samoa, and Northern Mariana Islands

July 15, 2021

FORM C

CARE2CARE INTERNATIONAL LLC



Up to \$400,000 of Convertible Promissory Notes

This Form C (including the cover page and all exhibits attached hereto, the "Form C") is being furnished by Care2Care International LLC, a New Hampshire Limited Liability Company (the "Company," as well as references to "we," "us," or "our"), to prospective investors for the sole purpose of providing certain information about a potential investment in convertible promissory notes of the Company (the "Securities"). Investors in Securities are sometimes referred to herein as "Purchasers." The Company intends to raise at least \$10,000.00 and up to \$400,000.00 from Investors in the offering of Securities described in this Form C (this "Offering"). The minimum amount of Securities that can be purchased is \$200.00 per Investor (which may be waived by the Company, in its sole and absolute discretion). The offer made hereby is subject to modification, prior sale and withdrawal at any time.

The rights and obligations of the holders of Securities of the Company are set forth below in the section entitled "*The Offering and the Securities--The Securities*". In order to purchase Securities, a prospective investor must complete the subscription process through the Intermediary's platform, which may be accepted or rejected by the Company, in its sole and absolute discretion. The Company has the right to cancel or rescind its offer to sell the Securities at any time and for any reason.

The Offering is being made through TyconoInvest.com (the "Intermediary"). The Intermediary will be entitled to receive 5% of the amount raised in the Offering.

	Price to Investors	Service Fees and Commissions (1)(2)	Net Proceeds
Minimum Individual Purchase Amount	\$200.00	\$10.00	\$190.00
Aggregate Minimum Offering Amount	\$10,000.00	\$500.00	\$9,500.00
Aggregate Maximum Offering Amount	\$400,000.00	\$20,000.00	\$380,000.00

- (1) This excludes fees to Company's advisors, such as attorneys and accountants.
(2) The Intermediary will receive 5% of the amount raised in the Offering.

A crowdfunding investment involves risk. You should not invest any funds in this Offering unless you can afford to lose your entire investment. In making an investment decision, investors must rely on their own examination of the issuer and the terms of the Offering, including the merits and risks involved. These Securities have not been recommended or approved by any federal or state securities commission or regulatory authority. Furthermore, these authorities have not passed upon the accuracy or adequacy of this document. The U.S. Securities and Exchange Commission does not pass upon the merits of any Securities offered or the terms of the Offering, nor does it pass upon the accuracy or completeness of any Offering document or other materials. These Securities are offered under an exemption from registration; however, neither the U.S. Securities and Exchange Commission nor any state securities authority has made an independent determination that these Securities are exempt from registration. The Company filing this Form C for an offering in reliance on Section 4(a)(6) of the Securities Act and pursuant to Regulation CF (§ 227.100 et seq.) must file a report with the Commission annually and post the report on its website at www.care2careinternational.com no later than 120 days after the end of the company's fiscal year. The Company may terminate its reporting obligations in the future in accordance with Rule 202(b) of Regulation CF (§ 227.202(b)) by 1) being required to file reports under Section 13(a) or Section 15(d) of the Exchange Act of 1934, as amended, 2) filing at least one annual report pursuant to Regulation CF and having fewer than 300 holders of record, 3) filing annual reports for three years pursuant to Regulation CF and having assets equal to or less than \$10,000,000, 4) the repurchase of all the Securities sold in this Offering by the Company or another party, or 5) the liquidation or dissolution of the Company.

The date of this Form C is July 15, 2021.

The Company has certified that all of the following statements are TRUE for the Company in connection with this Offering:

- (1) Is organized under, and subject to, the laws of a State or territory of the United States or the District of Columbia;
- (2) Is not subject to the requirement to file reports pursuant to section 13 or section 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m or 78o(d));
- (3) Is not an investment company, as defined in section 3 of the Investment Company Act of 1940 (15 U.S.C. 80a-3), or excluded from the definition of investment company by section 3(b) or section 3(c) of that Act (15 U.S.C. 80a-3(b) or 80a-3(c));
- (4) Is not ineligible to offer or sell securities in reliance on section 4(a)(6) of the Securities Act (15 U.S.C. 77d(a)(6)) as a result of a disqualification as specified in § 227.503(a);
- (5) Has filed with the Commission and provided to investors, to the extent required, any ongoing annual reports required by law during the two years immediately preceding the filing of this Form C; and
- (6) Has a specific business plan, which is not to engage in a merger or acquisition with an unidentified company or companies.

THERE ARE SIGNIFICANT RISKS AND UNCERTAINTIES ASSOCIATED WITH AN INVESTMENT IN THE COMPANY AND THE SECURITIES. THE SECURITIES OFFERED HEREBY ARE NOT PUBLICLY-TRADED AND ARE SUBJECT TO TRANSFER RESTRICTIONS. THERE IS NO PUBLIC MARKET FOR THE SECURITIES AND ONE MAY NEVER DEVELOP. AN INVESTMENT IN THE COMPANY IS HIGHLY SPECULATIVE. THE SECURITIES SHOULD NOT BE PURCHASED BY ANYONE WHO CANNOT BEAR THE FINANCIAL RISK OF THIS INVESTMENT FOR AN INDEFINITE PERIOD OF TIME AND WHO CANNOT AFFORD THE LOSS OF THEIR ENTIRE INVESTMENT. SEE THE SECTION OF THIS FORM C ENTITLED "RISK FACTORS."

THESE SECURITIES INVOLVE A HIGH DEGREE OF RISK THAT MAY NOT BE APPROPRIATE FOR ALL INVESTORS.

THIS FORM C DOES NOT CONSTITUTE AN OFFER IN ANY JURISDICTION IN WHICH AN OFFER IS NOT PERMITTED.

PRIOR TO CONSUMMATION OF THE PURCHASE AND SALE OF ANY SECURITY THE COMPANY WILL AFFORD PROSPECTIVE INVESTORS AN OPPORTUNITY TO ASK QUESTIONS OF AND RECEIVE ANSWERS FROM THE COMPANY AND ITS MANAGEMENT CONCERNING THE TERMS AND CONDITIONS OF THIS OFFERING AND THE COMPANY. NO SOURCE OTHER THAN THE INTERMEDIARY HAS BEEN AUTHORIZED TO GIVE ANY INFORMATION OR MAKE ANY REPRESENTATIONS OTHER THAN THOSE CONTAINED IN THIS FORM C, AND IF GIVEN OR MADE BY ANY OTHER SUCH PERSON OR ENTITY, SUCH INFORMATION MUST NOT BE RELIED ON AS HAVING BEEN AUTHORIZED BY THE COMPANY.

PROSPECTIVE INVESTORS ARE NOT TO CONSTRUE THE CONTENTS OF THIS FORM C AS LEGAL, ACCOUNTING OR TAX ADVICE OR AS INFORMATION NECESSARILY APPLICABLE TO EACH PROSPECTIVE INVESTOR'S PARTICULAR FINANCIAL SITUATION. EACH INVESTOR SHOULD CONSULT HIS OR HER OWN

FINANCIAL ADVISER, COUNSEL AND ACCOUNTANT AS TO LEGAL, TAX AND RELATED MATTERS CONCERNING HIS OR HER INVESTMENT.

THE SECURITIES OFFERED HEREBY WILL HAVE TRANSFER RESTRICTIONS. NO SECURITIES MAY BE PLEDGED, TRANSFERRED, RESOLD OR OTHERWISE DISPOSED OF BY ANY INVESTOR EXCEPT PURSUANT TO RULE 501 OF REGULATION CF. INVESTORS SHOULD BE AWARE THAT THEY WILL BE REQUIRED TO BEAR THE FINANCIAL RISKS OF THIS INVESTMENT FOR AN INDEFINITE PERIOD OF TIME.

NASAA UNIFORM LEGEND

IN MAKING AN INVESTMENT DECISION INVESTORS MUST RELY ON THEIR OWN EXAMINATION OF THE PERSON OR ENTITY ISSUING THE SECURITIES AND THE TERMS OF THE OFFERING, INCLUDING THE MERITS AND RISKS INVOLVED.

THESE SECURITIES HAVE NOT BEEN RECOMMENDED BY ANY FEDERAL OR STATE SECURITIES COMMISSION OR REGULATORY AUTHORITY. FURTHERMORE, THE FOREGOING AUTHORITIES HAVE NOT CONFIRMED THE ACCURACY OR DETERMINED THE ADEQUACY OF THIS DOCUMENT. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE.

SPECIAL NOTICE TO FOREIGN INVESTORS

IF THE INVESTOR LIVES OUTSIDE THE UNITED STATES, IT IS THE INVESTOR'S RESPONSIBILITY TO FULLY OBSERVE THE LAWS OF ANY RELEVANT TERRITORY OR JURISDICTION OUTSIDE THE UNITED STATES IN CONNECTION WITH ANY PURCHASE OF THE SECURITIES, INCLUDING OBTAINING REQUIRED GOVERNMENTAL OR OTHER CONSENTS OR OBSERVING ANY OTHER REQUIRED LEGAL OR OTHER FORMALITIES. THE COMPANY RESERVES THE RIGHT TO DENY THE PURCHASE OF THE SECURITIES BY ANY FOREIGN INVESTOR.

NOTICE REGARDING ESCROW AGENT

PRIME TRUST LLC, THE ESCROW AGENT SERVICING THE OFFERING, HAS NOT INVESTIGATED THE DESIRABILITY OR ADVISABILITY OF AN INVESTMENT IN THIS OFFERING OR THE SECURITIES OFFERED HEREIN. THE ESCROW AGENT MAKES NO REPRESENTATIONS, WARRANTIES, ENDORSEMENTS, OR JUDGEMENT ON THE MERITS OF THE OFFERING OR THE SECURITIES OFFERED HEREIN. THE ESCROW AGENT'S CONNECTION TO THE OFFERING IS SOLELY FOR THE LIMITED PURPOSES OF ACTING AS A SERVICE PROVIDER.

DISCLAIMER OF PRESENTATIONS

The Company's officers may participate in presentations at various forums and in the course of the presentations may present certain business information to the persons in attendance (the "Presentation"). The Company will not pass upon the merits of, certify, approve, or otherwise authorize the statements made in the Presentation. The Presentation commentary being made should not be viewed as superior or a substitute for the disclosures made in this Form-C. Accordingly, the statements made in the Presentation, unless reiterated in the offering materials provided herein, should not be applied to the Company's business and operations as of the date of this offering. Moreover, the Presentation may involve several statements constituting puffery, that is, exaggerations not to be taken literally or otherwise as indication of factual data or historical or future performance.

FORWARD-LOOKING STATEMENTS

This Form C and any documents incorporated by reference herein or therein contain forward-looking statements and are subject to risks and uncertainties. All statements other than statements of historical fact or relating to present facts or current conditions included in this Form C are forward-looking statements. Forward-looking statements give the Company's current reasonable expectations and projections relating to its financial condition, results of operations, plans, objectives, future performance and business. You can identify forward-looking statements by the fact that they do not relate strictly to historical or current facts. These statements may include words such as "anticipate," "estimate," "expect," "project," "plan," "intend," "believe," "may," "should," "can have," "likely" and other words and terms of similar meaning in connection with any discussion of the timing or nature of future operating or financial performance or other events.

The forward-looking statements contained in this Form C and any documents incorporated by reference herein or therein are based on reasonable assumptions the Company has made in light of its industry experience, perceptions of historical trends, current conditions, expected future developments and other factors it believes are appropriate under the circumstances. As you read and consider this Form C, you should understand that these statements are not guarantees of performance or results. They involve risks, uncertainties (many of which are beyond the Company's control) and assumptions. Although the Company believes that these forward-looking statements are based on reasonable assumptions, you should be aware that many factors could affect its actual operating and financial performance and cause its performance to differ materially from the performance anticipated in the forward-looking statements. Should one or more of these risks or uncertainties materialize, or should any of these assumptions prove incorrect or change, the Company's actual operating and financial performance may vary in material respects from the performance projected in these forward-looking statements.

Any forward-looking statement made by the Company in this Form C or any documents incorporated by reference herein or therein speaks only as of the date of this Form C. Factors or events that could cause our actual operating and financial performance to differ may emerge from time to time, and it is not possible for the Company to predict all of them. The Company undertakes no obligation to update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law.

Table of Contents

SUMMARY OF BUSINESS AND OFFERING.....	10
The Business	10
The Offering.....	11
RISK FACTORS	12
Risks Related to the Company’s Business and Industry	12
Risks Related to the Securities.....	21
BUSINESS	24
Description of the Business.....	24
Business Plan	24
Current Stage and Roadmap	25
Other Material Information.....	26
USE OF PROCEEDS.....	27
DIRECTORS, OFFICERS AND EMPLOYEES	28
Managing Members.....	28
Employees.....	29
OWNERSHIP AND CAPITALIZATION	29
Ownership	29
Valuation.....	29
FINANCIAL INFORMATION.....	29
Liquidity and Capital Resources	30
Capital Expenditures and Other Obligations	30
THE OFFERING AND THE SECURITIES.....	30
The Offering.....	30
The Securities.....	31
Interest Payment and Amortization Schedule.....	32
Conversion	32
Other Material Terms	33
TAX MATTERS.....	34
TRANSACTIONS WITH RELATED PERSONS AND CONFLICTS OF INTEREST.....	35
OTHER MATERIAL INFORMATION.....	35
EXHIBITS	37

About this Form C

This Form C is submitted consistent with the information and representations contained in the Company's "Test the Waters" offering <https://tycooninvest.com/care2care/ttw>.

You should rely only on the information contained in this Form C. We have not authorized anyone to provide you with information different from that contained in this Form C. We are offering to sell, and seeking offers to buy the Securities only in jurisdictions where offers and sales are permitted. You should assume that the information contained in this Form C is accurate only as of the date of this Form C, regardless of the time of delivery of this Form C or of any sale of Securities. Our business, financial condition, results of operations, and prospects may have changed since that date.

Statements contained herein as to the content of any agreements or other document are summaries and, therefore, are necessarily selective and incomplete and are qualified in their entirety by the actual agreements or other documents. The Company will provide the opportunity to ask questions of and receive answers from the Company's management concerning terms and conditions of the Offering, the Company or any other relevant matters and any additional reasonable information to any prospective Investor prior to the consummation of the sale of the Securities.

This Form C does not purport to contain all of the information that may be required to evaluate the Offering and any recipient hereof should conduct its own independent analysis. The statements of the Company contained herein are based on information believed to be reliable. No warranty can be made as to the accuracy of such information or that circumstances have not changed since the date of this Form C. The Company does not expect to update or otherwise revise this Form C or other materials supplied herewith. The delivery of this Form C at any time does not imply that the information contained herein is correct as of any time subsequent to the date of this Form C. This Form C is submitted in connection with the Offering described herein and may not be reproduced or used for any other purpose.

SUMMARY OF BUSINESS AND OFFERING

The following summary is qualified in its entirety by more detailed information that may appear elsewhere in this Form C and the Exhibits hereto. Each prospective Investor is urged to read this Form C and the Exhibits hereto in their entirety. The information available on or through our website is not a part of this Form C. In making an investment decision with respect to our Securities, you should only consider the information contained in this Form C.

The Business

Care2Care International LLC (the "Company") is a New Hampshire Limited Liability Company, formed on February 20, 2021.

The Company is located at: 70 Meadow Road, Portsmouth, NH 03801, and its website is: www.care2careinternational.com.

The company was co-founded by Andre Wencker and Pascal Orliac.

Care2care was originally launched in 2017 in the Medical travel industry, aiming at assisting US patients to access affordable quality health care in selected French hospitals and clinics among.

We discovered meanwhile that due to different factors, such as language barrier, distance, cultural differences and perceptions on healthcare systems, this would be a difficult endeavor.

Meanwhile we discovered the possibilities of “Pharma Travel”, which were postponed by Covid 19 at the beginning of 2020.

Our young start-up then "pivoted" a second time, towards a pharmacy mail-order offer, built with a Canadian pharmacy partner.

We have a first distribution agreement with an HR consultant who distributes a range of HR solutions in his geographical area (Midwest, Greater Chicago).

We are presently looking for different types of partners:

- Strategic, to be able to propose a complete pharmacy offering. Drug cost is the health care component that has increased the most since Obamacare. Drug prices continue to rise faster than the rest of the health care services, particularly specialty drugs. Among these actors, PBMs (Pharmacy Benefits Managers) and more specifically Pass-through PBMs are our ideal goal.
- Distribution partners, to speed up our business growth; we are in discussions with a potential partner, who is well aware of all the strategic questions.
- Supply chain partners, particularly licensed distributors or wholesalers in Europe. We are currently in contact with several players in the region.
- Financial partners, to help fund our business development.

The company is currently pre-revenue, but has the operational and management capabilities in place to effectively execute its business plan. Projections for the next year indicate gross revenues of \$266,400 with a net income of \$81,400.

The Offering

Minimum number of Securities being offered	10,000
Total number of LLC Membership Units outstanding after Offering (If minimum amount reached)	10,000
Maximum amount of LLC Membership Units being offered	400,000
Total number of LLC Membership Units outstanding after Offering (If maximum amount reached)	400,000
Purchase price per Security	\$1.00

Minimum investment amount per investor	\$200.00
Offering deadline	January 1, 2022
Use of proceeds	See the description of the use of proceeds on page 27 hereof.
Voting Rights	Non-voting unit. See the description of the voting rights on page 33 hereof.

RISK FACTORS

Risks Related to the Company's Business and Industry

To date, we have not generated revenue, and therefore rely on external financing.

We are a startup company and our business model currently focuses on the sale of our products. While we intend to generate revenue in the future, we cannot assure you when or if we will be able to do so.

We rely on external financing to fund our operations. We anticipate, based on our current proposed plans and assumptions relating to our operations (including the timetable of, and costs associated with, new product development) that, if the Maximum Amount is raised in this Offering, it will be sufficient to satisfy our contemplated cash requirements through approximately 12 months, assuming that we do not accelerate the development of other opportunities available to us, engage in an extraordinary transaction or otherwise face unexpected events, costs or contingencies, any of which could affect our cash requirements.

We expect capital outlays and operating expenditures to increase over the next several years as we expand our infrastructure, commercial operations, development activities and establish offices.

Our future funding requirements will depend on many factors, including but not limited to the following:

1. The cost of expanding our operations;
2. The financial terms and timing of any collaborations, licensing or other arrangements into which we may enter;
3. The rate of progress and cost of development activities;
4. The need to respond to technological changes and increased competition;
5. The costs of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights;
6. The cost and delays in product development that may result from changes in regulatory requirements applicable to our products;

- 7.Sales and marketing efforts to bring these new product candidates to market;
- 8.Unforeseen difficulties in establishing and maintaining an effective sales and distribution network; and
- 9.Lack of demand for and market acceptance of our products and technologies.

We may have difficulty obtaining additional funding and we cannot assure you that additional capital will be available to us when needed, if at all, or if available, will be obtained on terms acceptable to us. If we raise additional funds by issuing additional debt securities, such debt instruments may provide for rights, preferences or privileges senior to the Securities. In addition, the terms of the debt securities issued could impose significant restrictions on our operations. If we raise additional funds through collaborations and licensing arrangements, we might be required to relinquish significant rights to our technologies or product candidates, or grant licenses on terms that are not favorable to us. If adequate funds are not available, we may have to delay, scale back, or eliminate some of our operations or our research development and commercialization activities. Under these circumstances, if the Company is unable to acquire additional capital or is required to raise it on terms that are less satisfactory than desired, it may have a material adverse effect on its financial condition.

We have limited operating history upon which you can evaluate our performance, and accordingly, our prospects must be considered in light of the risks that any new company encounters.

We were organized under the laws of New Hampshire on February 20, 2021. Accordingly, we have no history upon which an evaluation of our prospects and future performance can be made. Our proposed operations are subject to all business risks associated with a new enterprise. The likelihood of our creation of a viable business must be considered in light of the problems, expenses, difficulties, complications, and delays frequently encountered in connection with the inception of a business, operation in a competitive industry, and the continued development of advertising, promotions, and a corresponding client base. We anticipate that our operating expenses will increase for the near future. There can be no assurances that we will ever operate profitably. You should consider the Company's business, operations and prospects in light of the risks, expenses and challenges faced as an early-stage company.

Members of our management team may make decisions detrimental to our business and/or be unable to successfully manage our operations. The ineffective management of our business will have a negative effect on our results of operations.

The development and commercialization of our products is highly competitive.

We face competition with respect to any products that we may seek to develop or commercialize in the future. Our competitors include major companies worldwide. Many of our competitors have significantly greater financial, technical and human resources than we have and superior expertise in research and development and marketing approved products and thus may be better equipped than us to develop and commercialize products. These competitors also compete with us in recruiting and retaining qualified personnel and acquiring technologies. Smaller or early stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. Accordingly, our competitors may commercialize products more rapidly or effectively than we are able to, which would adversely affect our competitive position, the likelihood that our products will achieve initial market acceptance and our ability to generate meaningful additional revenues from our products.

We rely on other companies to provide raw materials and finished goods for our products.

We depend on these suppliers and subcontractors to meet our contractual obligations to our customers and conduct our operations. Our ability to meet our obligations to our customers may be adversely affected if suppliers or subcontractors do not provide the agreed-upon supplies or perform the agreed-upon services in compliance with customer requirements and in a timely and cost-effective manner. Likewise, the quality of our products may be adversely impacted if companies to whom we delegate manufacture of major components or subsystems for our products, or from whom we acquire such items, do not provide raw materials and finished goods for our products, which meet required specifications and perform to our and our customers' expectations. Our suppliers may be less likely than us to be able to quickly recover from natural disasters and other events beyond their control and may be subject to additional risks such as financial problems that limit their ability to conduct their operations. The risk of these adverse effects may be greater in circumstances where we rely on only one or two subcontractors or suppliers for a particular raw material and/or finished good.

We depend on third-party service providers and outsource providers for a variety of services and we outsource a number of our non-core functions and operations.

In certain instances, we rely on single or limited service providers and outsourcing vendors because the relationship is advantageous due to quality, price, or lack of alternative sources. If production or service was interrupted and we were not able to find alternate third-party providers, we could experience disruptions in manufacturing and operations including product shortages, higher freight costs and re-engineering costs. If outsourcing services are interrupted or not performed or the performance is poor, this could impact our ability to process, record and report transactions with our customers and other constituents. Such interruptions in the provision of supplies and/or services could result in our inability to meet customer demand, damage our reputation and customer relationships and adversely affect our business.

Quality management plays an essential role in determining and meeting customer requirements, preventing defects, improving the Company's products and services and maintaining the integrity of the data that supports the safety and efficacy of our products.

Our future success depends on our ability to maintain and continuously improve our quality management program. An inability to address a quality or safety issue in an effective and timely manner may also cause negative publicity, a loss of customer confidence in us or our current or future products, which may result in the loss of sales and difficulty in successfully launching new products. In addition, a successful claim brought against us in excess of available insurance or not covered by indemnification agreements, or any claim that results in significant adverse publicity against us, could have an adverse effect on our business and our reputation.

In general, demand for our products and services is highly correlated with general economic conditions.

A substantial portion of our revenue is derived from discretionary spending by individuals, which typically falls during times of economic instability. Declines in economic conditions in the U.S. or in other countries in which we operate may adversely impact our consolidated financial results. Because such declines in demand are difficult to predict, we or the industry may have increased excess capacity as a result. An increase in excess capacity may result in declines in prices for our products and services.

The use of individually identifiable data by our business, our business associates and third parties is regulated at the state, federal and international levels.

Costs associated with information security – such as investment in technology, the costs of compliance with consumer protection laws and costs resulting from consumer fraud – could cause our business and results of operations to suffer materially. Additionally, the success of our online operations depends upon the secure transmission of confidential information over public networks, including the use of cashless payments. The intentional or negligent actions of employees, business associates or third parties may undermine our security measures. As a result, unauthorized parties may obtain access to our data systems and misappropriate confidential data. There can be no assurance that advances in computer capabilities, new discoveries in the field of cryptography or other developments will prevent the compromise of our customer transaction processing capabilities and personal data. If any such compromise of our security or the security of information residing with our business associates or third parties were to occur, it could have a material adverse effect on our reputation, operating results and financial condition. Any compromise of our data security may materially increase the costs we incur to protect against such breaches and could subject us to additional legal risk.

Through our operations, we collect and store certain personal information that our customers provide to purchase products or services, enroll in promotional programs, register on our web site, or otherwise communicate and interact with us.

We may share information about such persons with vendors that assist with certain aspects of our business. Security could be compromised and confidential customer or business information misappropriated. Loss of customer or business information could disrupt our operations, damage our reputation, and expose us to claims from customers, financial institutions, payment card associations and other persons, any of which could have an adverse effect on our business, financial condition and results of operations. In addition, compliance with tougher privacy and information security laws and standards may result in significant expense due to increased investment in technology and the development of new operational processes.

Security breaches and other disruptions could compromise our information and expose us to liability, which would cause our business and reputation to suffer.

We collect and store sensitive data, including intellectual property, our proprietary business information and that of our customers, suppliers and business partners, and personally identifiable information of our customers and employees, in our data centers and on our networks. The secure processing, maintenance and transmission of this information is critical to our operations and business strategy. Despite our security measures, our information technology and infrastructure may be vulnerable to attacks by hackers or breached due to employee error, malfeasance or other disruptions. Any such breach could compromise our networks and the information stored there could be accessed, publicly disclosed, lost or stolen. Any such access, disclosure or other loss of information could result in legal claims or proceedings, liability under laws that protect the privacy of personal information, and regulatory penalties, disrupt our operations and the services we provide to customers, and damage our reputation, and cause a loss of confidence in our products and services, which could adversely affect our business/operating margins, revenues and competitive position.

An intentional or unintentional disruption, failure, misappropriation or corruption of our network and information systems could severely affect our business.

Such an event might be caused by computer hacking, computer viruses, worms and other destructive or disruptive software, "cyber attacks" and other malicious activity, as well as natural disasters, power outages, terrorist attacks and similar events. Such events could have an adverse impact on us and our customers, including degradation of service, service disruption, excessive call volume to call centers and damage to our plant, equipment and data. In addition, our future

results could be adversely affected due to the theft, destruction, loss, misappropriation or release of confidential customer data or intellectual property. Operational or business delays may result from the disruption of network or information systems and the subsequent remediation activities. Moreover, these events may create negative publicity resulting in reputation or brand damage with customers.

The Company's success depends on the experience and skill of its board of members, and its executive officers and key employees.

In particular, the Company is dependent on Andre Wencker, Founder and CEO, and Pascal Orliac, Co-Founder and CMO, of the Company. The loss of Andre Wencker or Pascal Orliac, or any member of the board of directors or executive officer could harm the Company's business, financial condition, cash flow and results of operations.

Although dependent on certain key personnel, the Company does not have any key man life insurance policies on any such people.

The Company is dependent on Andre Wencker and Pascal Orliac in order to conduct its operations and execute its business plan, however, the Company has not purchased any insurance policies with respect to those individuals in the event of their death or disability. Therefore, if either of Andre Wencker or Pascal Orliac die or become disabled, the Company will not receive any compensation to assist with such person's absence. The loss of such person could negatively affect the Company and its operations.

We rely on third-party suppliers for the materials used in the manufacturing of our products.

If suppliers change their sales strategy to reduce its reliance on distribution channels, or decided to terminate its business relationship with us, sales and earnings could be adversely affected until we are able to establish relationships with suppliers of comparable products. Any delay or interruption in manufacturing operations (or failure to locate a suitable replacement for such suppliers) could materially adversely affect our business, prospects, or results of operations. Most of our agreements with suppliers are terminable by either party on short notice for any reason. Although we believe our relationships with these key suppliers are good, they could change their strategies as a result of a change in control, expansion of their direct sales force, changes in the marketplace or other factors beyond our control, including a key supplier becoming financially distressed.

We rely on various intellectual property rights, including licenses in order to operate our business.

Such intellectual property rights, however, may not be sufficiently broad or otherwise may not provide us a significant competitive advantage. In addition, the steps that we have taken to maintain and protect our intellectual property may not prevent it from being challenged, invalidated, circumvented or designed-around, particularly in countries where intellectual property rights are not highly developed or protected. In some circumstances, enforcement may not be available to us because an infringer has a dominant intellectual property position or for other business reasons, or countries may require compulsory licensing of our intellectual property. Our failure to obtain or maintain intellectual property rights that convey competitive advantage, adequately protect our intellectual property or detect or prevent circumvention or unauthorized use of such property, could adversely impact our competitive position and results of operations. We also rely on nondisclosure and noncompetition agreements with employees, consultants and other parties to protect, in part, trade secrets and other proprietary rights. There can be no assurance that these agreements will adequately protect our trade secrets and other proprietary rights and will not be breached, that we will have adequate remedies for any breach,

that others will not independently develop substantially equivalent proprietary information or that third parties will not otherwise gain access to our trade secrets or other proprietary rights.

As we expand our business, protecting our intellectual property will become increasingly important. The protective steps we have taken may be inadequate to deter our competitors from using our proprietary information. In order to protect or enforce our patent rights, we may be required to initiate litigation against third parties, such as infringement lawsuits. Also, these third parties may assert claims against us with or without provocation. These lawsuits could be expensive, take significant time and could divert management's attention from other business concerns. The law relating to the scope and validity of claims in the technology field in which we operate is still evolving and, consequently, intellectual property positions in our industry are generally uncertain. We cannot assure you that we will prevail in any of these potential suits or that the damages or other remedies awarded, if any, would be commercially valuable.

From time to time, third parties may claim that one or more of our products or services infringe their intellectual property rights.

Any dispute or litigation regarding patents or other intellectual property could be costly and time-consuming due to the uncertainty of intellectual property litigation and could divert our management and key personnel from our business operations. A claim of intellectual property infringement could force us to enter into a costly or restrictive license agreement, which might not be available under acceptable terms or at all, could require us to redesign our products, which would be costly and time-consuming, and/or could subject us to an injunction against development and sale of certain of our products or services. We may have to pay substantial damages, including damages for past infringement if it is ultimately determined that our products infringe on a third party's proprietary rights. Even if these claims are without merit, defending a lawsuit takes significant time, may be expensive and may divert management's attention from other business concerns. Any public announcements related to litigation or interference proceedings initiated or threatened against us could cause our business to be harmed. Our intellectual property portfolio may not be useful in asserting a counterclaim, or negotiating a license, in response to a claim of intellectual property infringement. In certain parts of our business we rely on third party intellectual property licenses and we cannot ensure that these licenses will be available to us in the future on favorable terms or at all.

We are subject to income taxes as well as non-income based taxes, such as payroll, sales, use, value-added, net worth, property and goods and services taxes, in both the U.S.

Significant judgment is required in determining our provision for income taxes and other tax liabilities. In the ordinary course of our business, there are many transactions and calculations where the ultimate tax determination is uncertain. Although we believe that our tax estimates are reasonable: (i) there is no assurance that the final determination of tax audits or tax disputes will not be different from what is reflected in our income tax provisions, expense amounts for non-income based taxes and accruals and (ii) any material differences could have an adverse effect on our financial position and results of operations in the period or periods for which determination is made.

We are not subject to Sarbanes-Oxley regulations and lack the financial controls and safeguards required of public companies.

We do not have the internal infrastructure necessary, and are not required, to complete an attestation about our financial controls that would be required under Section 404 of the Sarbanes-Oxley Act of 2002. There can be no assurance that there are no significant deficiencies or

material weaknesses in the quality of our financial controls. We expect to incur additional expenses and diversion of management's time if and when it becomes necessary to perform the system and process evaluation, testing and remediation required in order to comply with the management certification and auditor attestation requirements.

Changes in employment laws or regulation could harm our performance.

Various federal and state labor laws govern our relationship with our employees and affect operating costs. These laws include minimum wage requirements, overtime pay, healthcare reform and the implementation of the Patient Protection and Affordable Care Act, unemployment tax rates, workers' compensation rates, citizenship requirements, union membership and sales taxes. A number of factors could adversely affect our operating results, including additional government-imposed increases in minimum wages, overtime pay, paid leaves of absence and mandated health benefits, mandated training for employees, increased tax reporting and tax payment changing regulations from the National Labor Relations Board and increased employee litigation including claims relating to the Fair Labor Standards Act.

The Company's business operations may be materially adversely affected by a pandemic such as the Coronavirus (COVID-19) outbreak.

In December 2019, a novel strain of coronavirus was reported to have surfaced in Wuhan, China, which spread throughout other parts of the world, including the United States. On January 30, 2020, the World Health Organization declared the outbreak of the coronavirus disease (COVID-19) a "Public Health Emergency of International Concern." On January 31, 2020, U.S. Health and Human Services Secretary Alex M. Azar II declared a public health emergency for the United States to aid the U.S. healthcare community in responding to COVID-19, and on March 11, 2020 the World Health Organization characterized the outbreak as a "pandemic." COVID-19 resulted in a widespread health crisis that adversely affected the economies and financial markets worldwide. The Company's business could be materially and adversely affected. The extent to which COVID-19 impacts the Company's business will depend on future developments, which are highly uncertain and cannot be predicted, including new information which may emerge concerning the severity of COVID-19 and the actions to contain COVID-19 or treat its impact, among others. If the disruptions posed by COVID-19 or other matters of global concern continue for an extended period of time, the Company's operations may be materially adversely affected.

We face risks related to health epidemics and other outbreaks, which could significantly disrupt the Company's operations and could have a material adverse impact on us.

The outbreak of pandemics and epidemics could materially and adversely affect the Company's business, financial condition, and results of operations. If a pandemic occurs in areas in which we have material operations or sales, the Company's business activities originating from affected areas, including sales, materials, and supply chain related activities, could be adversely affected. Disruptive activities could include the temporary closure of facilities used in the Company's supply chain processes, restrictions on the export or shipment of products necessary to run the Company's business, business closures in impacted areas, and restrictions on the Company's employees' or consultants' ability to travel and to meet with customers, vendors or other business relationships. The extent to which a pandemic or other health outbreak impacts the Company's results will depend on future developments, which are highly uncertain and cannot be predicted, including new information which may emerge concerning the severity of a virus and the actions to contain it or treat its impact, among others. Pandemics can also result in social, economic, and labor instability which may adversely impact the Company's business.

If the Company's employees or employees of any of the Company's vendors, suppliers or customers become ill or are quarantined and in either or both events are therefore unable to

work, the Company's operations could be subject to disruption. The extent to which a pandemic affects the Company's results will depend on future developments that are highly uncertain and cannot be predicted.

The Company may be subject to various product liability claims, including, among others, that its products caused injury or illness, include inadequate instructions for use or include inadequate warnings concerning possible side effects or interactions with other substances.

A product liability claim or regulatory action against the Company could result in increased costs, could adversely affect the Company's reputation, and could have a material adverse effect on its business and operational results.

The Company's success and future will depend, to a significant degree, on the continued efforts of its members, officers and key employees, including certain technical individuals, and sales and marketing personnel, the retention of which cannot be guaranteed.

The loss of key personnel could materially adversely affect the Company's business. The loss of any such personnel could harm or delay the plans of the Company's business either while management time is directed to finding suitable replacements (who, in any event, may not be available), or, if not, covering such vacancy until suitable replacements can be found. In either case, this may have a material adverse effect on the future of the Company's business. Competition for such personnel can be intense, and the Company cannot provide assurance that it will be able to attract or retain highly qualified technical, sales, marketing and management personnel in the future.

The Company is exposed to the risk that any of its employees, independent contractors and consultants may engage in fraudulent or other illegal activity.

Misconduct by these parties could include intentional, reckless and/or negligent conduct or disclosure of unauthorized activities to the Company that violates, (i) government regulations, (ii) manufacturing standards, or (iii) laws that require the true, complete and accurate reporting of financial information or data. It may not always be possible for the Company to identify and deter misconduct by its employees and other third parties, and the precautions taken by the Company to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting the Company from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. If any such actions are instituted against the Company, and it is not successful in defending itself or asserting its rights, those actions could have a significant impact on the business of the Company, including the imposition of civil, criminal and administrative penalties, damages, monetary fines, contractual damages, reputational harm, diminished profits and future earnings, and curtailment of the operations of the Company, any of which could have a material adverse effect on the business, financial condition, results of operations or prospects of the Company.

The success of the Company will depend, in part, on the ability of the Company to maintain and enhance trade secret protection over their existing and potential proprietary techniques and processes.

The Company may be vulnerable to competitors who develop competing technology, whether independently or as a result of acquiring access to the proprietary products and trade secrets of the Company. In addition, effective future patent, copyright and trade secret protection may be unavailable or limited in certain foreign countries and may be unenforceable under the laws of certain jurisdictions. Failure of the Company to adequately maintain and enhance protection over its proprietary techniques and processes could have a materially adverse impact on the business,

financial condition and operating results of the Company.

The Company may become party to litigation from time to time in the ordinary course of business which could adversely affect its business.

Should any litigation in which the Company becomes involved be determined against it, such a decision could adversely affect the ability of the Company to continue operating and could use significant resources. Even if the Company is involved in litigation and wins, litigation can redirect significant resources.

The business of the Company is subject to the impact of changes in national or North American economic conditions including, but not limited to, recessionary or inflationary trends, equity market conditions, consumer credit availability, interest rates, consumers' disposable income and spending levels, job security and unemployment, and overall consumer confidence.

These economic conditions may be further affected by political events throughout the world that cause disruptions in the financial markets, either directly or indirectly. Adverse economic and political developments could have a material adverse effect on the business, financial condition, results of operations or prospects of the Company.

The Company believes its industry is highly dependent upon consumer perception regarding the safety, efficacy and quality of its products and perceptions of regulatory compliance.

Consumer perception of the Company's products can be significantly influenced by regulatory investigations, litigation, media attention and other publicity. There can be no assurance that future regulatory proceedings, litigation, media attention or other research findings or publicity will be favorable to the Company's market or any particular product, or consistent with earlier publicity. The Company's dependence upon consumer perceptions means that adverse regulatory proceedings, litigation, media attention or other publicity, whether or not accurate or with merit, could have a material adverse effect on the Company, the demand for products, and the business, results of operations, financial condition and cash flows of the Company. Further, adverse publicity reports or other media attention regarding the safety, efficacy and quality of Company's products in general could have such a material adverse effect.

Risks Associated with Numerous Laws and Regulations:

The production, labeling and distribution of the products that the Company proposes to distribute are regulated by various federal, provincial, state and local agencies. These governmental authorities may commence regulatory or legal proceedings, which could restrict the permissible scope of the Company's ability to sell its products in the future.

Constraints on Marketing Products:

The development of the Company's business and operating results may be hindered by applicable restrictions on sales and marketing activities imposed by government regulatory bodies. The regulatory environment in the United States limits the Company's ability to compete for market share in a manner similar to other industries. If the Company is unable to effectively market its products and compete for market share, or if the costs of compliance with government legislation and regulation cannot be absorbed through increased selling prices for its products, the Company's sales and operating results could be adversely affected.

Risks Related to the Securities

The Securities will not be freely tradable until one year from the initial purchase date. Although the Securities may be tradable under federal securities law, state securities regulations may apply and each Purchaser should consult with his or her attorney.

You should be aware of the long-term nature of this investment. There is not now and likely will not be a public market for the Securities. Because the Securities have not been registered under the Securities Act or under the securities laws of any state or non-United States jurisdiction, the Securities have transfer restrictions and cannot be resold in the United States except pursuant to Rule 501 of Regulation CF. It is not currently contemplated that registration under the Securities Act or other securities laws will be effected. Limitations on the transfer of the Securities may also adversely affect the price that you might be able to obtain for the Securities in a private sale. Purchasers should be aware of the long-term nature of their investment in the Company. Each Purchaser in this Offering will be required to represent that it is purchasing the Securities for its own account, for investment purposes and not with a view to resale or distribution thereof.

Neither the Offering nor the Securities have been registered under federal or state securities laws, leading to an absence of certain regulation applicable to the Company.

No governmental agency has reviewed or passed upon this Offering, the Company or any Securities of the Company. The Company also has relied on exemptions from securities registration requirements under applicable state securities laws. Investors in the Company, therefore, will not receive any of the benefits that such registration would otherwise provide. Prospective investors must therefore assess the adequacy of disclosure and the fairness of the terms of this Offering on their own or in conjunction with their personal advisors.

No Guarantee of Return on Investment

There is no assurance that a Purchaser will realize a return on its investment or that it will not lose its entire investment. For this reason, each Purchaser should read the Form C and all Exhibits carefully and should consult with its own attorney and business advisor prior to making any investment decision.

A majority of the Company is owned by a small number of owners.

Prior to the Offering the Company's current owners of 20% or more beneficially own up to 100.0% of the Company. Subject to any fiduciary duties owed to our other owners or investors under New Hampshire law, these owners may be able to exercise significant influence over matters requiring owner approval, including the election of directors or managers and approval of significant Company transactions, and will have significant control over the Company's management and policies. Some of these persons may have interests that are different from yours. For example, these owners may support proposals and actions with which you may disagree. The concentration of ownership could delay or prevent a change in control of the Company or otherwise discourage a potential acquirer from attempting to obtain control of the Company, which in turn could reduce the price potential investors are willing to pay for the Company. In addition, these owners could use their voting influence to maintain the Company's existing management, delay or prevent changes in control of the Company, or support or reject other management and board proposals that are subject to owner approval.

The Company has the right to extend the Offering deadline.

The Company may extend the Offering deadline beyond what is currently stated herein. This means that your investment may continue to be held in escrow while the Company attempts to raise the Minimum Amount even after the Offering deadline stated herein is reached. Your

investment will not be accruing interest during this time and will simply be held until such time as the new Offering deadline is reached without the Company receiving the Minimum Amount, at which time it will be returned to you without interest or deduction, or the Company receives the Minimum Amount, at which time it will be released to the Company to be used as set forth herein. Upon or shortly after release of such funds to the Company, the Securities will be issued and distributed to you.

Your ownership of the shares of stock will be subject to dilution.

Owners of do not have preemptive rights. If the Company conducts subsequent Offerings of or Securities convertible into, issues shares pursuant to a compensation or distribution reinvestment plan or otherwise issues additional shares, investors who purchase shares in this Offering who do not participate in those other stock issuances will experience dilution in their percentage ownership of the Company's outstanding shares. Furthermore, shareholders may experience a dilution in the value of their shares depending on the terms and pricing of any future share issuances (including the shares being sold in this Offering) and the value of the Company's assets at the time of issuance.

The Securities will be equity interests in the Company and will not constitute indebtedness.

The Securities will rank junior to all existing and future indebtedness and other non-equity claims on the Company with respect to assets available to satisfy claims on the Company, including in a liquidation of the Company. Additionally, unlike indebtedness, for which principal and interest would customarily be payable on specified due dates, there will be no specified payments of dividends with respect to the Securities and dividends are payable only if, when and as authorized and declared by the Company and depend on, among other matters, the Company's historical and projected results of operations, liquidity, cash flows, capital levels, financial condition, debt service requirements and other cash needs, financing covenants, applicable state law, federal and state regulatory prohibitions and other restrictions and any other factors the Company's board of directors deems relevant at the time. In addition, the terms of the Securities will not limit the amount of debt or other obligations the Company may incur in the future. Accordingly, the Company may incur substantial amounts of additional debt and other obligations that will rank senior to the Securities.

There can be no assurance that we will ever provide liquidity to Purchasers through either a sale of the Company or a registration of the Securities.

There can be no assurance that any form of merger, combination, or sale of the Company will take place, or that any merger, combination, or sale would provide liquidity for Purchasers. Furthermore, we may be unable to register the Securities for resale by Purchasers for legal, commercial, regulatory, market-related or other reasons. In the event that we are unable to effect a registration, Purchasers could be unable to sell their Securities unless an exemption from registration is available.

The Company does not anticipate paying any cash dividends for the foreseeable future.

The Company currently intends to retain future earnings, if any, for the foreseeable future, to repay indebtedness and to support its business. The Company does not intend in the foreseeable future to pay any dividends to holders of its shares of .

In addition to the risks listed above, businesses are often subject to risks not foreseen or fully appreciated by the management. It is not possible to foresee all risks that may affect us. Moreover, the Company cannot predict whether the Company will successfully effectuate the Company's current business plan. Each prospective Purchaser is encouraged to carefully analyze

the risks and merits of an investment in the Securities and should take into consideration when making such analysis, among other, the Risk Factors discussed above.

There is no present market for the Securities and we have arbitrarily set the price.

We have arbitrarily set the price of the Securities with reference to the general status of the securities market and other relevant factors. The Offering price for the Securities should not be considered an indication of the actual value of the Securities and is not based on our net worth or prior earnings. We cannot assure you that the Securities could be resold by you at the Offering price or at any other price.

The Company has the right to conduct multiple closings during the Offering.

If the Company meets certain terms and conditions, and more than thirty (30) days remain before the Offering Deadline, an intermediate close of the Offering can occur, which will allow the Company to draw down on the first \$10,000 of the proceeds of the offering committed and captured during the relevant period, as well as any amounts raised after. The Company may choose to continue the Offering thereafter. Purchasers should be mindful that this means they can make multiple investment commitments in the Offering, which may be subject to different cancellation rights. For example, if an intermediate close occurs and later a material change occurs as the Offering continues, Purchasers previously closed upon will not have the right to re-confirm their investment as it will be deemed completed.

In addition to the risks listed above, businesses are often subject to risks not foreseen or fully appreciated by the management. It is not possible to foresee all risks that may affect us. Moreover, the Company cannot predict whether the Company will successfully effectuate the Company's current business plan. Each prospective Purchaser is encouraged to carefully analyze the risks and merits of an investment in the Securities and should take into consideration when making such analysis, among other, the Risk Factors discussed above.

THE SECURITIES OFFERED INVOLVE A HIGH DEGREE OF RISK AND MAY RESULT IN THE LOSS OF YOUR ENTIRE INVESTMENT. ANY PERSON CONSIDERING THE PURCHASE OF THESE SECURITIES SHOULD BE AWARE OF THESE AND OTHER FACTORS SET FORTH IN THIS FORM C AND SHOULD CONSULT WITH HIS OR HER LEGAL, TAX AND FINANCIAL ADVISORS PRIOR TO MAKING AN INVESTMENT IN THE SECURITIES. THE SECURITIES SHOULD ONLY BE PURCHASED BY PERSONS WHO CAN AFFORD TO LOSE ALL OF THEIR INVESTMENT.

BUSINESS

Description of the Business

Care2Care International LLC (the "Company") generates revenue through the sale of its products (as highlighted above) direct to consumer online, consumers at sporting and other events, and mass retail channels. The Company is currently pre-revenue, but is ready to launch its products within the next 30 days.

Business Plan

Our mission is to be the premiere provider of affordable medications for healthcare plans and individuals. The Care2Care brand will be known as a brand that builds lasting relationships with our customers and clients, and consistently delivers exceptional value.

Medications are the fastest growing expense for health care plans, due mainly to price increases in the medications. Medications now represent ~25% of health plan costs, with US prices often 4-times higher than those of other high-income countries, especially for specialty medications.

Care2Care solves this issue by providing a comprehensive solution on pharmacy spending:

1. International sourcing of specialty drugs. Care2Care is not a pharmacy; rather an intermediary agent working with licensed pharmacies.
2. Provision only US FDA approved drugs. No injectables or temperature-controlled medications.
3. Offer a complete solution in partnership with other drug cost containment actors, such as Pharmacy Benefit Managers, MAPs' Administrators, NDC11 "Disruptors" and others.
4. Service aimed mainly at Self-Insured Employers, and also welcome non-insured or under-insured individuals.
5. Deliver huge savings for hundreds of costly prescription drugs.

We focus on high-demand claimants: people with 2 or more chronic conditions, which represent only 2-5% of the insured population, but account for 50-70% of plan medication costs; and deliver a very strong value proposition:

1. Access same quality specialty, high-cost prescription drugs at a much lower cost for Patients and Employers.
2. Cost containment for self-insured plan sponsors.
3. Short term employee incentives to facilitate adoption (no copay and/or deductible, etc.)
4. Long-term employee health maintenance/improvement, hence long-term health care plan cost stability.
5. One solution for our Benefits Partners to add value in a very competitive market.

We focus on customer segments with large concentrations of claimants that could realize significant benefits from our services, such as:

1. Benefits brokers, TPAs, Consultants - We have an active file of more than 1000 contacts among these professionals; TPAs are an outstanding actor, due to their proximity with plan members
2. Stop-loss insurance professionals in search of cost reduction while preventing carving out of costly drugs.
3. Midsized, self-insured Employers are the ultimate target; they are generally very dependent on the benefits professionals.
4. Employees and Plan Members the end users of the program, particularly those with multiple costly conditions.

5. Individual patients we have particularly received requests from Medicare patients affected by the “donut-hole” issue in their plan

We partner and collaborate with highly-competent members of the healthcare ecosystem who are dedicated to deliver effective and affordable healthcare:

1. International licensed pharmacies in Canada and Europe.
2. Benefits brokers, TPAs, Consultant and others,
3. Stop-loss insurers and re-insurers.
4. Self-insured employers and HR Benefits Managers.
5. Healthcare cost containment experts such as PBM, MAP Administrators, NDC11 Analysis and Formulary Managers.
6. IT experts such as web developers, SEO experts and specialists in lead generation and call center services.

We design, develop, implement, and manage industrial-strength, efficient, timely and accurate methods to consistently deliver operational excellence, including:

1. Sales and Marketing
2. Monitoring online workflow platforms.
3. Patient program adoption and retention.
4. Patient enrollment assistance.
5. Supply chain management.
6. Pre and Post operations valuation of savings and medication data analysis.

We employ a pricing model which constitutes a win-win proposition for all constituencies:

1. We negotiate the best price in different companies and add a performance fee based on the actual savings achieved.
2. Fee is a percentage of the savings using the US coupon or NADAC process as the benchmark.
3. The performance fee percentage increase with the price differential factor and decrease with the dollar value.
4. The fee for service includes shipping, handling and physician services. Tele-consultation is provided at an additional, nominal price.
5. We provide full transparency to the acquisition price and performance fee in bills to payers.

Current Stage and Roadmap

We are in active discussions with a “Pass Through” PBM, offering a full solution for drug costs containment (MAP, Pharmacogenomics , rebate aggregator, clinical counseling on the formulary, etc.)

We are also in advanced discussion with a possible partner: a Health Care consultant influent in the field; could enter as partner, providing referrals to his customer base

We are engaged with not-for-profit players in lobbying efforts aimed at securing the legal aspects of the activity. There has been, and still is, a current, bipartisan support to these efforts

We are launching our 2021 sales campaign, once the negotiations mentioned above are finalized.

During 2021, we will look to hire a full-time experienced sales representative, and incur reasonable operating expenses for marketing, travel, temporary personnel, external services and other necessary operating expenses. The founders shall remain unpaid, and will be the workforce for the bulk of the work.

In 2022-2023, we will look to scale to full activity level. The founders will be on payroll when appropriate.

As a result our efforts, we expect to achieve a solid customer mix on which to further grow the business:

2021	2022-2023
4 partners (TPA, Brokers, etc.)	10 partners
40 employers	100 employers
500 covered members each	500 covered members each
20,000 covered members	50,000 covered members

Other Material Information

There are no existing legal suits pending, or to the Company’s knowledge, threatened, against the Company.

Because this Form C focuses primarily on information concerning the Company rather than the industry in which the Company operates, potential Purchasers may wish to conduct their own separate investigation of the Company’s industry to obtain greater insight in assessing the Company’s prospects.

USE OF PROCEEDS

The following table lists the use of proceeds of the Offering if the Minimum Amount and Maximum Amount are raised.

Use of Proceeds	% of Minimum Proceeds Raised	Amount if Minimum Raised	% of Maximum Proceeds Raised	Amount if Maximum Raised
Intermediary Fees	5.00%	\$500	5.00%	\$20,000
Campaign marketing expenses or related reimbursement	0.00%	\$0	0.00%	\$0
Estimated Attorney Fees	0.00%	\$0	0.00%	\$0
Estimated Accountant/Auditor Fees	0.00%	\$0	0.00%	\$0
General Marketing	0.00%	\$0	85.00%	\$340,000
Research and Development	0.00%	\$0	0.00%	\$0
Manufacturing	0.00%	\$0	0.00%	\$0
Future Wages	0.00%	\$0	0.00%	\$0
General Working Capital	95.00%	\$9,500	10.00%	\$40,000
Total	100.00%	\$10,000	100.00%	\$400,000

The Use of Proceeds chart is not inclusive of fees paid for use of the Form C generation system, payments to financial and legal service providers, and escrow related fees, all of which were incurred in preparation of the campaign and are due in advance of the closing of the campaign.

The Company does have discretion to alter the use of proceeds as set forth above. The Company may alter the use of proceeds under the following circumstances: Subject to changing market conditions.

DIRECTORS, OFFICERS AND EMPLOYEES

MANAGING MEMBERS

Managing Member: Andre Wencker is the Founder and CEO of Care2Care.

Positions and Offices currently held with the issuer:

- Position: CEO
- Dates of Service: February 20, 2021-Present
- Responsibilities: Andre's key purpose is to ensure the company's prosperity by collectively directing the company's affairs, whilst meeting the appropriate interests of its shareholders and stakeholders.

André held multiple leadership and executive positions as CFO, GM and CEO in the health insurance industry, both mandatory and supplemental, and in the retirement pension sector: Gras Savoye (largest French insurance broker), Maaf-Santé, CAMAC, and MGC Mutual.

He is the owner and Principal at AWA Conseil, a Business consulting firm he started in 2002 in the French supplemental health insurance sector, more specifically focusing on business development and innovation.

André is a graduate from HEC Paris (#1 Business School in Europe), with an MS in Business Administration, holds an Executive Health MBA EHESP and ESCP Europe – 2013 (Comparative study and analysis of primary health systems in the developed world), and is a member of the French Institute of Actuaries since 1995.

Andre is a member of the board of the non-for-profit Foundation FORCE, aimed at financing medical research in the Eastern region of France.

Andre is CEO of Care2Care SARL, a company organized under the laws of France, which is the Member of record for this Company, Care2Care International LLC, a New Hampshire limited liability company.

Managing Member: Pascal Orliac is the Co-Founder and Chief Marketing Officer of Care2Care.

Positions and Offices currently held with the issuer:

- Position: CMO
- Dates of Service: February 20, 2021-Present
- Responsibilities: Andre's key purpose is to ensure the company's prosperity by collectively directing the company's affairs, with particular emphasis on marketing activities, whilst meeting the appropriate interests of its shareholders and stakeholders.

Pascal is a Lecturer at the University of New Hampshire's Peter T. Paul College of Business and Economics, and a member of the Board of Advisors of Pragmatic Consulting Inc.

As Global VPHR of Goss International, Pascal directed the design and implementation of HR strategies and practices in the Americas, Europe and Asia-Pacific. He started his career as an entrepreneur and was co-founder of two start-up companies in the Tourism industry in France. Pascal

holds a MBA from HEC Paris, France, and a Bachelor degree in Management Sciences with concentrations in Marketing and Finance from Paris University.

He is a member of the Board of Directors of the Birchtree Center, a non-profit school helping children and youth with autism grow and flourish in their families and communities.

Indemnification

Indemnification is authorized by the Company to directors, officers or controlling persons acting in their professional capacity pursuant to New Hampshire law. Indemnification includes expenses such as attorney's fees and, in certain circumstances, judgments, fines and settlement amounts actually paid or incurred in connection with actual or threatened actions, suits or proceedings involving such person, except in certain circumstances where a person is adjudged to be guilty of gross negligence or willful misconduct, unless a court of competent jurisdiction determines that such indemnification is fair and reasonable under the circumstances.

Employees

The Company currently has 2 employees in New Hampshire, USA.

OWNERSHIP AND CAPITALIZATION

Ownership

The Company has issued the following outstanding Membership interest:

Name of Member	Type of Security Held	% of Voting Power Prior to Offering
Pascal Orliac	LLC Ownership Interest	1.0%
Care2Care SARL	LLC Membership Interest	99.0%

The Company does not have any debt outstanding.

Valuation

The Company is pre-revenue, and is presently valued at \$1,539,394 based on discounted cash flow of forecasted net operating profit and funding methods.

FINANCIAL INFORMATION

Please see the financial information listed on the cover page of this Form C and attached hereto in addition to the following information. Financial statements are attached hereto as Exhibit A.

Liquidity and Capital Resources

The Offering proceeds are essential to our operations. We plan to use the proceeds as set forth above under "use of proceeds", which is an indispensable element of our business strategy. The Offering proceeds will have a beneficial effect on our liquidity, as we currently have \$100 in cash on hand which will be augmented by the Offering proceeds and used to execute our business strategy.

Capital Expenditures and Other Obligations

The Company does not intend to make any material capital expenditures in the future.

THE OFFERING AND THE SECURITIES

The Offering

The Company is offering Convertible Promissory Notes (the "Securities" or "Notes") for up to \$400,000.00 for a per Security price of \$1.00. The Company is attempting to raise a minimum amount of \$10,000.00 in this Offering (the "Minimum Amount"). The Company must receive commitments from investors in an amount totaling the Minimum Amount by January 1, 2022 (the "Offering Deadline") in order to receive any funds. If the sum of the investment commitments does not equal or exceed the Minimum Amount by the Offering Deadline, no Securities will be sold in the Offering, investment commitments will be cancelled and committed funds will be returned to potential investors without interest or deductions. The Company has the right to extend the Offering Deadline at its discretion. The Company will accept investments in excess of the

Minimum Amount up to \$400,000.00 (the "Maximum Amount") and the additional Securities will be allocated on a first-come, first-served basis.

The price of the Securities does not necessarily bear any relationship to the Company's asset value, net worth, revenues or other established criteria of value, and should not be considered indicative of the actual value of the Securities.

In order to purchase the Securities you must make a commitment to purchase by completing the Subscription Agreement and/or Convertible Promissory Note. Purchaser funds will be held in escrow with North Capital Financial Services until the Minimum Amount of investments is reached. Pursuant to SEC Rule §227.201(z)(1)(iv)(D) the Company is limiting Purchaser cancellations after 48 hours following their commitment unless there is a material change in the Offering. Any such cancellation can be done using the cancellation mechanism provided by the Intermediary. The Company will notify Purchasers when the Minimum Amount has been reached. If the Company reaches the Minimum Amount prior to the Offering Deadline, it may close the Offering at least five (5) days after reaching the Minimum Amount and providing notice to the Purchasers. If any material change (other than reaching the Minimum Amount) occurs related to the Offering prior to the Offering Deadline, the Company will provide notice to Purchasers and receive reconfirmations from Purchasers who have already made commitments. If a Purchaser does not reconfirm his or her investment commitment after a material change is made to the terms of the Offering, the Purchaser's investment commitment will be cancelled and

the committed funds will be returned without interest or deductions. If a Purchaser does not cancel an investment commitment before the Minimum Amount is reached, the funds will be released to the Company upon closing of the Offering and the Purchaser will receive the Securities in exchange for his or her investment. Any Purchaser funds received after the initial closing will be released to the Company upon a subsequent closing and the Purchaser will receive Securities via Electronic Certificate/PDF in exchange for his or her investment as soon as practicable thereafter.

In the event that \$10,000 in investments is committed and received by the escrow agent and more than thirty (30) days remain before the Offering Deadline, the Company may conduct the first of multiple closings of the Offering (an "Intermediate Close"), provided all investors receive notice that an Intermediate Close will occur and funds will be released to the Company, at least five (5) business days prior to the Intermediate Close (absent a material change that would require an extension of the offering and reconfirmation of the investment commitment). Investors who committed on or before such notice will have until 48 hours before the Intermediate Close to cancel their investment commitment. In the event the Company does conduct the first of multiple closes, the Company agrees to only withdraw \$100,000 from escrow and will only conduct the Intermediate Close if more than thirty (30) days remain before the Offering Deadline.

The Company has agreed to return all funds to investors in the event a Form C-W is ultimately filed in relation to this Offering, regardless of any subsequent closes.

The Notes are not binding on the Company until accepted by the Company, which reserves the right to reject, in whole or in part, in its sole and absolute discretion, any subscription. If the Company rejects all or a portion of any subscription, the applicable prospective Purchaser's funds will be returned without interest or deduction.

The price of a single Security is \$1.00. The price of the Securities was determined arbitrarily by the Company and a Purchase should not rely on such price as a determination of the market value of such Securities.

The minimum amount that a Purchaser may invest in the Offering is \$200.00.

The Offering is being made through TycoonoInvest Portal, the Intermediary. The following field below sets forth the compensation being paid in connection with the Offering.

Commission/Fees

5.0% of the amount raised in the Offering.

The Securities

We request that you please review our organizational documents in conjunction with the following summary information.

Authorized Capitalization

At the initial closing of this Offering (if the Minimum Amount is sold), our authorized Membership Units will consist of 2,000,000 units, zero par value per unit, of which 2,000,000 units will be issued and outstanding.

Interest Payment and Amortization Schedule

The minimum principal amount of any single Note is \$200.00.

The Notes will have an original issue discount of 20% (the “Discount”).

The Notes will mature on the date that is two (2) years from the Closing (the “Maturity Date”). The

Notes are prepayable by the Company.

The Notes will pay interest at a rate of 6% per annum.

The notes are non-amortizing and the entire principal amount will be due and payable at maturity, unless converted earlier.

Subordination

The Notes are not subordinate to other indebtedness of the Company.

Events of Default

In addition to the standard events of default such the Company’s failure to pay principal and/or interest on the Notes, liquidation of the Company and voluntary or involuntary bankruptcy proceedings of the Company, the following are additional events of default pursuant to the Notes: None.

Conversion

The Notes will convert as follows:

1. **Next Equity Financing Conversion.** The principal balance and unpaid accrued interest on the Note will automatically convert into either shares of the equity securities issued in the Next Equity Financing (“Conversion Units”) upon the closing of the Company’s next equity financing round in a single transaction or a series of related transactions yielding gross proceeds to the Company of at least \$5,000,000 in the aggregate(excluding the conversion of the Note) (the “Next Equity Financing”). The number of Conversion Units the Company issues upon such conversion will equal the quotient (rounded down to the nearest whole share) obtained by dividing (A) the outstanding principal balance and unpaid accrued interest under the Note on a date that is no more than five (5) days prior to the closing of the Next Equity Financing/the date of conversion by (B) the lesser of (i) the lowest per share purchase price in the Next Equity Financing multiplied by the Discount, and (ii) the quotient of a pre-money value for the Company equal to \$2,000,000 (the “Valuation Cap”) divided by the number of the Company’s fully-diluted capital stock immediately before the closing of the Qualified Financing (the “Fully Diluted Capitalization”).

2. Corporate Transaction Conversion. In the event of a Corporate Transaction prior to the conversion or repayment of the Note, at the closing of such Corporate Transaction, Investor may elect that either: (a) the Company will pay Investor an amount equal to the sum of (x) all accrued and unpaid interest due on the Note and (y) the outstanding principal balance of this Note; or (b) the Note will convert into that number of the Company's Common Stock equal to the quotient (rounded down to the nearest whole share) obtained by dividing (x) the outstanding principal balance and unpaid accrued interest of the Note on a date that is no more than five (5) days prior to the closing of such Corporate Transaction/the date of conversion by (y) the quotient resulting from dividing the Valuation Cap by the Fully Diluted Capitalization immediately prior to the closing of the Corporate Transaction.

“Corporate Transaction” means:

(i) the closing of the sale, transfer or other disposition, in a single transaction or series of related transactions, of all or substantially all of the Company's assets;

(ii) the consummation of a merger or consolidation of the Company with or into another entity (except a merger or consolidation in which the holders of capital stock of the Company immediately prior to such merger or consolidation continue to hold a majority of the outstanding voting securities of the capital stock of the Company or the surviving or acquiring entity immediately following the consummation of such transaction); or

(iii) the closing of the transfer (whether by merger, consolidation or otherwise), in a single transaction or series of related transactions, to "person" or "group" (within the meaning of Section 13(d) and Section 14(d) of the Exchange Act), of the Company's capital stock if, after such closing, such person or group would become the "beneficial owner" (as defined in Rule 13d3 under the Exchange Act) of more than 50% of the outstanding voting securities of the Company (or the surviving or acquiring entity).

2. Maturity Conversion. At any time on or after the Maturity Date, at the option of the Investors holding a majority of the aggregate principal amount of the Notes (the “Requisite Noteholders”), the entire principal amount and accrued interest of each Note shall (i) be paid to Investor or (ii) be converted into shares of the Company's Common Stock at a conversion price equal to the quotient resulting from dividing the Valuation Cap by the Fully Diluted Capitalization.

Other Material Terms

Not Currently Equity Interests

The Securities are not currently equity interests in the Company and can be thought of as the right to receive shares at some point in the future upon the occurrence of certain events.

Voting and Control

The Securities have the following voting rights: No voting rights. Upon conversion, shares of Shadow Preferred will have no voting rights and shares of Common Stock will have voting rights.

The Company does not have any voting agreements in place.

The Company does not have any shareholder/equity holder agreements in place.

Anti-Dilution Rights

The Securities do not have anti-dilution rights.

Restrictions on Transfer

Any Securities sold pursuant to Regulation CF being offered may not be transferred by any Investor of such Securities during the one-year holding period beginning when the Securities were issued, unless such Securities were transferred: 1) to the Company, 2) to an accredited investor, as defined by Rule 501(d) of Regulation D of the Securities Act of 1933, as amended, 3) as part of an Offering registered with the SEC or 4) to a member of the family of the Investor or the equivalent, to a trust controlled by the Investor, to a trust created for the benefit of a family member of the Investor or the equivalent, or in connection with the death or divorce of the Investor or other similar circumstances. "Member of the family" as used herein means a child, stepchild, grandchild, parent, stepparent, grandparent, spouse or spousal equivalent, sibling, mother/father/daughter/son/sister/brother-in-law, and includes adoptive relationships. Remember that although you may legally be able to transfer the Securities, you may not be able to find another party willing to purchase them.

The Company does have the right to repurchase the Convertible Promissory Notes.

TAX MATTERS

EACH PROSPECTIVE INVESTOR SHOULD CONSULT WITH HIS OR HER OWN TAX AND ERISA ADVISOR AS TO THE PARTICULAR CONSEQUENCES TO THE INVESTOR OF THE PURCHASE, OWNERSHIP AND SALE OF THE INVESTOR'S SECURITIES, AS WELL AS POSSIBLE CHANGES IN THE TAX LAWS.

TO INSURE COMPLIANCE WITH THE REQUIREMENTS IMPOSED BY THE INTERNAL REVENUE SERVICE, WE INFORM YOU THAT ANY TAX STATEMENT IN THIS FORM C CONCERNING UNITED STATES FEDERAL TAXES IS NOT INTENDED OR WRITTEN TO BE USED, AND CANNOT BE USED, BY ANY TAXPAYER FOR THE PURPOSE OF AVOIDING ANY TAX-RELATED PENALTIES UNDER THE UNITED STATES INTERNAL REVENUE CODE. ANY TAX STATEMENT HEREIN CONCERNING UNITED STATES FEDERAL TAXES WAS WRITTEN IN CONNECTION WITH THE MARKETING OR PROMOTION OF THE TRANSACTIONS OR MATTERS TO WHICH THE STATEMENT RELATES. EACH TAXPAYER SHOULD SEEK ADVICE BASED ON THE TAXPAYER'S PARTICULAR CIRCUMSTANCES FROM AN INDEPENDENT TAX ADVISOR.

Potential Investors who are not United States residents are urged to consult their tax advisors regarding the United States federal income tax implications of any investment in the Company, as well as the taxation of such investment by their country of residence. Furthermore, it should be anticipated that distributions from the Company to such foreign investors may be subject to UNITED STATES withholding tax.

EACH POTENTIAL INVESTOR SHOULD CONSULT HIS OR HER OWN TAX ADVISOR CONCERNING THE POSSIBLE IMPACT OF STATE TAXES.

TRANSACTIONS WITH RELATED PERSONS AND CONFLICTS OF INTEREST

Related Person Transactions

From time to time the Company may engage in transactions with related persons. Related persons are defined as any director or officer of the Company; any person who is the beneficial owner of 10 percent or more of the Company's outstanding voting equity securities, calculated on the basis of voting power; any promoter of the Company; any immediate family member of any of the foregoing persons or an entity controlled by any such person or persons.

The Company has not conducted transactions with related persons:

Conflicts of Interest

To the best of our knowledge the Company has not engaged in any transactions or relationships, which may give rise to a conflict of interest with the Company, its operations or its security holders.

OTHER MATERIAL INFORMATION

Bad Actor Disclosure

The Company is not subject to any Bad Actor Disqualifications under any relevant U.S. securities laws.

ONGOING REPORTING

The Company will file a report electronically with the Securities & Exchange Commission annually and post the report on its website, no later than 120 days after the end of the company's fiscal year.

Once posted, the annual report may be found on the Company's website: www.care2careinternational.com

The Company must continue to comply with the ongoing reporting requirements until:

- (1) the Company is required to file reports under Section 13(a) or Section 15(d) of the Exchange Act;
- (2) the Company has filed at least three annual reports pursuant to Regulation CF and has total assets that do not exceed \$10,000,000;
- (3) the Company has filed at least one annual report pursuant to Regulation CF and has fewer than 300 holders of record;
- (4) the Company or another party repurchases all of the Securities issued in reliance on Section 4(a)(6) of the Securities Act, including any payment in full of debt securities or any complete redemption of redeemable securities; or
- (5) the Company liquidates or dissolves its business in accordance with state law.

[SIGNATURE PAGE FOLLOWS]

SIGNATURE

Pursuant to the requirements of Sections 4(a)(6) and 4A of the Securities Act of 1933 and Regulation Crowdfunding (§ 227.100 et seq.), the issuer certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form C and has duly caused this Form to be signed on its behalf by the duly authorized undersigned.

RA WENCKER

Andre Wencker, Founder, CEO

Orliac

Pascal Orliac, Co-Founder, CMO

Pursuant to the requirements of Sections 4(a)(6) and 4A of the Securities Act of 1933 and Regulation Crowdfunding (§ 227.100 et seq.), this Form C has been signed by the following persons in the capacities and on the dates indicated.

RA WENCKER

Andre Wencker, Founder, CEO

Orliac

Pascal Orliac, Co-Founder, CMO

Instructions.

1. The form shall be signed by the issuer, its principal executive officer or officers, its principal financial officer, its controller or principal accounting officer and at least a majority of the board of directors or persons performing similar functions.
2. The name of each person signing the form shall be typed or printed beneath the signature.

Intentional misstatements or omissions of facts constitute federal criminal violations. See 18 U.S.C. 1001.

EXHIBITS

- Exhibit A Financial Statements
- Exhibit B Financial Forecast
- Exhibit C Video Transcript
- Exhibit D Reg CF Test-the-Waters Posting

EXHIBIT A
Financial Statements

FINANCIAL STATEMENTS



**FOR THE PERIOD FEBRUARY 20, 2021
(DATE OF FORMATION)
THROUGH APRIL 30, 2021**

CARE2CARE INTERNATIONAL, LLC

CONTENTS

	PAGE NO.
INDEPENDENT ACCOUNTANT'S REVIEW REPORT	2
Balance Sheet, as of April 30, 2021	3
Statement of Operations, for the Period February 20, 2021 (Date of Formation) through April 30, 2021	4
Statement of Members' Equity, for the Period February 20, 2021 (Date of Formation) through April 30, 2021	5
Statement of Cash Flows, for the Period February 20, 2021 (Date of Formation) through April 30, 2021	6
NOTES TO FINANCIAL STATEMENTS	7 - 9



CPAs & ADVISORS

INDEPENDENT ACCOUNTANT'S REVIEW REPORT

To the Board of Directors
Care2Care International, LLC
Portsmouth, New Hampshire

We have reviewed the accompanying financial statements of Care2Care International, LLC (the Company), a Limited Liability Corporation, which comprise the balance sheets as of April 30, 2021, and the related statements of operations, members' equity and cash flows for the period February 20, 2021 through April 30, 2021 and the related notes to the financial statements. A review includes primarily applying analytical procedures to management's financial data and making inquiries of company management. A review is substantially less in scope than an audit, the objective of which is the expression of an opinion regarding the financial statements as a whole. Accordingly, we do not express such an opinion.

Management's Responsibility for the Financial Statements

Management is responsible for the preparation and fair presentation of these financial statements in accordance with accounting principles generally accepted in the United States of America; this includes the design, implementation and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free from material misstatement, whether due to fraud or error.

Accountant's Responsibility

Our responsibility is to conduct the review engagement in accordance with Statements on Standards for Accounting and Review Services promulgated by the Accounting and Review Services Committee of the AICPA. Those standards require us to perform procedures to obtain limited assurance as a basis for reporting whether we are aware of any material modifications that should be made to the financial statements for them to be in accordance with accounting principles generally accepted in the United States of America. We believe that the results of our procedures provide a reasonable basis for our conclusion.

Accountant's Conclusion

Based on our reviews, we are not aware of any material modifications that should be made to the accompanying financial statements in order for them to be in accordance with accounting principles generally accepted in the United States of America.

A handwritten signature in black ink that reads "Gelman Rosenberg & Freedman". The signature is written in a cursive, flowing style.

June 22, 2021

4550 MONTGOMERY AVENUE • SUITE 800 NORTH • BETHESDA, MARYLAND 20814
(301) 951-9090 • WWW.GRFCPA.COM

MEMBER OF CPAMERICA INTERNATIONAL, AN AFFILIATE OF CROWE GLOBAL
MEMBER OF THE AMERICAN INSTITUTE OF CERTIFIED PUBLIC ACCOUNTANTS' PRIVATE COMPANIES PRACTICE SECTION

CARE2CARE INTERNATIONAL, LLC

**BALANCE SHEET
AS OF APRIL 30, 2021**

ASSETS

CURRENT ASSETS

Cash and cash equivalents \$ 100

TOTAL ASSETS **\$ 100**

MEMBERS' EQUITY

Members' equity \$ 100

TOTAL MEMBERS' EQUITY **\$ 100**

CARE2CARE INTERNATIONAL, LLC

**STATEMENT OF OPERATIONS
FOR THE PERIOD FEBRUARY 20, 2021 (DATE OF FORMATION) THROUGH APRIL 30, 2021**

REVENUE	\$ -
COST OF SALES	-
GROSS PROFIT ON SALES	-
SELLING, GENERAL AND ADMINISTRATIVE EXPENSES	-
NET INCOME	\$ -

CARE2CARE INTERNATIONAL, LLC

STATEMENT OF MEMBERS' EQUITY
FOR THE PERIOD FEBRUARY 20, 2021 (DATE OF FORMATION) THROUGH APRIL 30, 2021

	<u>Members' Equity</u>
Balance, February 20, 2021	\$ -
Issuance of member units	<u>100</u>
BALANCE, APRIL 30, 2021	<u>\$ 100</u>

CARE2CARE INTERNATIONAL, LLC

**STATEMENT OF CASH FLOWS
FOR THE PERIOD FEBRUARY 20, 2021 (DATE OF FORMATION) THROUGH APRIL 30, 2021**

CASH FLOWS FROM OPERATING ACTIVITIES

Net income	\$ -
Adjustments to reconcile net income to net cash provided by operating activities:	<u>-</u>
Net cash provided by operating activities	<u>-</u>

CASH FLOWS FROM FINANCING ACTIVITIES

Contributions from members	<u>100</u>
Net increase in cash and cash equivalents	100
Cash and cash equivalents at beginning of period	<u>-</u>
CASH AND CASH EQUIVALENTS AT END OF PERIOD	<u><u>\$ 100</u></u>

CARE2CARE INTERNATIONAL, LLC

**NOTES TO FINANCIAL STATEMENTS
FEBRUARY 20, 2021 (DATE OF FORMATION) THROUGH APRIL 30, 2021**

1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND GENERAL INFORMATION

Organization -

Care2Care International, LLC (the Company) is a limited liability company formed on February 20, 2021 in the State of New Hampshire.

The Company forms agreements with health care plans and individual patients to provide prescription medications to patients through mail order programs with local medical pharmacies.

As of April 30, 2021, the Company has commenced operations, but no revenues and expenses have occurred. During the next twelve months, the Company intends to fund its operations with funding from a crowdfunding campaign (see Note 3) and from revenue producing activities, if and when such can be realized.

Basis of presentation -

The accompanying financial statements are presented on the accrual basis of accounting, which presents financial position, results of operations and cash flows in accordance with accounting principles generally accepted in the United States of America.

Cash and cash equivalents -

The Company considers all cash and other highly liquid investments with initial maturities of three months or less to be cash equivalents.

Revenue recognition -

The Company enters into agreements with medical pharmacies and doctors to provide medical benefits to eligible participants. Contracts generally have a two year term, but are cancellable by either party with 60 days notice. Performance obligations are satisfied as prescription medication is transferred to the participant. Generally, prescriptions are transferred to the participants twice a month and revenue is recognized when the pharmacies and doctors provide medication to the participants. The term between invoicing and when performance obligations are satisfied is not significant. Payment terms are typically due concurrently with the delivery of services. There are no significant financing components or significant payment terms. There were no revenues for the period February 20, 2021 through April 30, 2021.

Income taxes -

The Company, with the consent of its members, has elected to be treated as a partnership under the provisions of the Internal Revenue Code. Accordingly, the Company is not subject to Federal or state income taxes.

CARE2CARE INTERNATIONAL, LLC

**NOTES TO FINANCIAL STATEMENTS
FEBRUARY 20, 2021 (DATE OF FORMATION) THROUGH APRIL 30, 2021**

**1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND GENERAL INFORMATION
(Continued)**

Uncertain tax positions -

For the period ended April 30, 2021, the Company has documented its consideration of FASB ASC 740-10, Income Taxes, that provides guidance for reporting uncertainty in income taxes and has determined that no material uncertain tax positions qualify for either recognition or disclosure in the financial statements.

Use of estimates -

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Accordingly, actual results could differ from those estimates.

New accounting pronouncements (not yet adopted) -

FASB issued ASU 2019-01, Leases (Topic 842). The ASU changes the accounting treatment for operating leases by recognizing a lease asset and lease liability at the present value of the lease payments in the Balance Sheets and disclosing key information about leasing arrangements. During 2020, the FASB issued ASU 2020-05 and delayed the implementation date by one year. The ASU is effective for nonpublic entities beginning after December 15, 2021. Early adoption is still permitted. The ASU can be applied at the beginning of the earliest period presented using a modified retrospective approach or applied at the beginning of the period of adoption recognizing a cumulative-effect adjustment. The Company plans to adopt the new ASU at the required implementation date and management is currently in the process of evaluating the adoption method and the impact of the new standard on its accompanying financial statements.

Economic uncertainties -

On March 11, 2020, the World Health Organization declared the Coronavirus disease (COVID-19) a global pandemic. As a result of the spread of COVID-19, economic uncertainties have arisen which may negatively impact the Company's operations. The overall potential impact is unknown at this time.

2. RELATED PARTY TRANSACTIONS

The Company conducts transactions with Care2Care Société à responsabilité limitée (SARL), which is a French entity owned by the members of the Company. There were no related party transactions for the period ending April 30, 2021.

3. CROWDFUNDING OFFERING

The Company is offering (the "Crowdfunding Offering") up to \$400,000 in Simple Agreements for Future Equity (SAFEs). The Company is attempting to raise a minimum amount of \$10,000 in this offering and up to \$400,000 maximum. The Company must receive commitments from investors totaling the minimum amount by the offering deadline listed in the Form C, as amended in order to receive any funds. The Crowdfunding Offering is being made through Tycooninvest.

CARE2CARE INTERNATIONAL, LLC

**NOTES TO FINANCIAL STATEMENTS
FEBRUARY 20, 2021 (DATE OF FORMATION) THROUGH APRIL 30, 2021**

4. SUBSEQUENT EVENTS

In preparing these financial statements, the Company has evaluated events and transactions for potential recognition or disclosure through June 22, 2021, the date the financial statements were issued.

EXHIBIT B

Financial Forecasts

The above-signed officers of Care2Care International LLC hereby certify that the financial condition of the Company expressed in this Offering is accurate, true and complete in all material respects. As this is a startup business, there are no financial statements to review. We certify that all statements of fact about the Company included in this Offering are accurate and complete to the best of our knowledge.

The following are forecasts of financial results for the first 3 years of operations.

(\$000)	2021	2022	2023
Sales			
Performance fees	\$266.40	\$686.20	\$1,130.40
Expenses			
Sales manager	\$100.00	\$105.00	\$110.25
Executive Team		\$100.00	\$200.00
Temp personnel	\$15.00	\$20.00	\$25.00
Travel & Accommodations	\$30.00	\$30.00	\$30.00
External Services	\$15.00	\$20.00	\$30.00
Marketing expenses	\$20.00	\$30.00	\$40.00
Supplies & Misc.	\$5.00	\$10.00	\$15.00
S/T Expenses	\$185.00	\$315.00	\$450.25
Profit (Loss)	\$81.40	\$371.20	\$680.15

EXHIBIT C

Video Transcript

Americans pay between 3 and 5 times more for prescription drugs than other high-income countries!

As one former American President officially stated: “this is for the exact same drugs, sometimes produced in the same plant!

This has immediate and direct consequences on people's lives.

Look for instance at Tina ’s and her son’s Tim, situation:

Tina has Type II Diabetes and Tim asthma.

Every month she encounters the same problem: how will she make it to pay for her Jardiance, and Tim’s Anoro Ellipta?

Tina finally had a discussion with John the Benefits manager of her company.

John had heard about Care2care and its International Prescription Mail-Order Program.

He knew they had built a partnership with a network of experienced pharmacists, located in Canada and European countries providing drugs at much lower prices.

During the meeting they set up, the Care2care’s sales representative explains their solution; he recommends that the employer waive the plan deductible and pharmacy copay.

Thanks to the huge savings C2C provides, Tina and her son will get their medicine for free, and the employer will still pay way less!

Their 3-month supply for Jardiance costs \$397 (instead of \$1577) and Tim’s Anoro Ellipta \$153 vs \$416

For Tina, the solution is convenient:

1. She signs in on Care2care user-friendly secure patient portal;
2. She selects their medications, uploads their prescriptions, and sends the order to the Pharmacy

At every step, the pharmacy is here to help via toll-free hotline, email and fax

3. An order confirmation is sent via email;
4. The Shipment is confirmed.

Tina will receive their medications directly in her mailbox, usually in about 2 weeks from the order confirmation.

Tina and Tim are not alone: over 4 million Americans use this solution every year. Employers, States, (Utah is the last and very recent example, and local governments have implemented Personal Importation Programs for their health plan members.

At Care2care we are confident that the personal importation market can only grow, since Prescription drug costs continue to rise faster than general prices.

And our Performance fee is a win-win: it's a function of the amount of savings between a US benchmark price and the acquisition cost for the client.

Join us! Join the growing Care2care community!

EXHIBIT D

Reg CF Test-the Waters Posting

Care2Care is currently in the TEST THE WATERS phase for Regulation Crowdfunding Investments

CARE2CARE

Enabling delivery of affordable medications for healthcare plans and individuals



Portsmouth, NH
Services

The mission is to be the premier provider of internationally sourced affordable medications for healthcare plans and individuals. Care2Care International will be known as a brand that builds lasting relationships with customers and plan members, and consistently delivers exceptional value.

Terms

Debt / Equity	Conv. Notes
Offering Type	Security
\$1.00	\$200
Price per Note	Min. Reservation
\$154M	TTW
Pre-Money Valuation	Offering

RESERVE NOW

This Reg CF Test the Waters offering is made available through Tycooninvest Portal LLC

Reserving securities is simply an indication of interest that involves no obligation or commitment of any kind.

- Opportunity
- Offering Terms
- Updates
- Q&A

WHY INVEST IN CARE2CARE?

- Well-established, far-reaching ecosystem to become the premier provider of internationally sourced affordable medications for a vast market of self-insured healthcare plans and under-insured individuals.
- Provides a simple solution for procuring US FDA-approved medications delivering huge savings for hundreds of costly prescription drugs.
- Focus on 2-5% of the insured population, accounting for over 50% of pharmacy plan costs and delivering savings of up to 80%.
- Highly experienced team that partners and collaborates with experts of the healthcare ecosystem who are dedicated to delivering effective and affordable healthcare.
- Multiple revenue stream business model with estimated Year 3 net operating income of \$680K on total revenue of \$1.1 million.

MANAGEMENT TEAM

André Wencker, Founder and CEO

André held multiple leadership and executive positions as CFO, CM, and CEO in the health insurance industry, both mandatory and supplemental, and in the retirement pension sector: Gras Savoye (largest French insurance broker), Maaf-Santé, CAMAC, and MGC Mutual.

He is the owner and Principal at AWA Consell, a Business consulting firm he started in 2002 in the French supplemental health insurance sector, more specifically focusing on business development and innovation.

André is a graduate from HEC Paris (#1 Business School in Europe), with an MS in Business Administration, holds an Executive Health MBA EHESP and ESCP Europe – 2013 (Comparative study and analysis of primary health systems in the developed world), and is a member of the French Institute of Actuaries since 1995.

André is a member of the board of the not-for-profit Foundation FORCE, aimed at financing medical research in the Eastern region of France.

André is CEO of Care2Care SARL, a company organized under the laws of France, which is the main shareholder of record for this Company, Care2Care International LLC, a New Hampshire limited liability company.

Pascal Oriac, Co-Founder and Chief Marketing Officer

Pascal is a Lecturer at the University of New Hampshire's Peter T. Paul College of Business and Economics, and a member of the Board of Advisors of Pragmatic Consulting Inc.

As Global VPHR of Goss International, Pascal directed the design and implementation of HR strategies and practices in the Americas, Europe, and Asia-Pacific. He started his career as an entrepreneur and was co-founder of two start-up companies in the Tourism industry in France. Pascal holds an MBA from HEC Paris, France, and a Bachelor's degree in Management Sciences with concentrations in Marketing and Finance from Paris University.

He is a member of the Board of Directors of the Birchtree Center, a non-profit school helping children and youth with autism grow and flourish in their families and communities.



© Tycooninvest 2020-2021. All rights reserved.

For Companies

- Raise Capital
- Why Tycooninvest
- The Process for Companies
- Company FAQ
- Investment Crowdfunding Basics

For Investors

- Invest
- The Process for Investors
- Investor FAQ
- Investor Disclosures
- Investment Crowdfunding Basics

About

- Refer Businesses
- About Us
- Careers
- Terms of Use
- Privacy Policy
- Contact Us

IMPORTANT MESSAGE

INVESTORS MUST RELY ON THEIR OWN EXAMINATION OF THE OFFERING AND THE TERMS OF THE OFFERING, INCLUDING THE MERITS AND RISKS INVOLVED, WHEN MAKING AN INVESTMENT DECISION. INVESTMENTS ON TYCOONINVEST ARE SPECULATIVE, ILLIQUID, AND INVOLVE A HIGH DEGREE OF RISK, INCLUDING THE POSSIBLE LOSS OF YOUR ENTIRE INVESTMENT.

Investment opportunities that are posted and accessible through this website are Regulation Crowdfunding offerings (JOBS Act Title III, Section 4(a)(2)), which are offered to non-accredited and accredited investors alike. These offerings are made through Tycooninvest Portal LLC (aka Tycooninvest), a funding portal registered with the US Securities and Exchange Commission (SEC), and a member of the Financial Industry Regulatory Authority (FINRA, CRD#313156).

Accordingly, Tycooninvest Portal LLC does not offer investment advice or recommendations; solicit purchases, sales, or offers to buy the securities offered or displayed on its portal; compensate employees, agents, or other persons for such solicitation or based on the sale of securities displayed or referenced on its platform or portal; or hold, manage, possess, or otherwise handle investor funds or securities.

Any securities offered on this website have not been recommended or approved by any federal or state securities commission or regulatory authority. Tycooninvest and its affiliates do not provide any investment advice or recommendation and do not provide any legal or tax advice with respect to any securities. All securities listed on this site are being offered by, and all information included on this site is the responsibility of, the applicable issuer of such securities. Tycooninvest does not verify the adequacy, accuracy, or completeness of any information. Neither Tycooninvest nor any of its officers, directors, agents, and employees makes any warranty, express or implied, of any kind whatsoever with respect to the adequacy, accuracy, or completeness of any information on this site or the use of information on this site. See our general disclaimer here.

TYCOON INC. runs Tycooninvest.com and Tycooninvest.com, and is the parent company of Tycooninvest Portal LLC. Tycooninvest Portal LLC is a funding portal that operates sections of Tycooninvest.com and Tycooninvest.com where Regulation Crowdfunding offerings are made. TYCOON INC. the parent company is not regulated as either a broker-dealer or funding portal and is not a member of FINRA.

By accessing this site and any pages on this site, you agree to be bound by our Terms of Use and Privacy Policy. It may be amended from time to time without notice or liability. Potential investors are strongly advised to consult their legal, tax, and financial advisors before investing. The securities offered on this site are not offered in jurisdictions where public solicitation for offerings is not permitted, it is solely your responsibility to comply with the laws and regulations of your country of residence.

Care2Care is currently in the TEST THE WATERS phase for Regulation Crowdfunding investments

CARE2CARE

Enabling delivery of affordable medications for healthcare plans and individuals



Portsmouth, NH
Services

The mission is to be the premier provider of internationally sourced affordable medications for healthcare plans and individuals. Care2Care International will be known as a brand that builds lasting relationships with customers and plan members, and consistently delivers exceptional value.

Terms

Debt / Equity	Conv. Notes
Offering Type	Security
\$1.00	\$200
Price per Note	Min. Reservation
\$1.54M	TTW
Pre-Money Valuation	Offering

RESERVE NOW

*This Reg CF Test the Waters offering is made available through TycoonInvest Portal LLC
Reserving securities is simply an indication of interest that involves no obligation or commitment of any kind.*

- Opportunity
- Offering Terms**
- Updates
- Q&A

Offering Summary

Company: Care2Care International LLC
Address: 70 Meadow Road, Portsmouth, NH 03801
Minimum Investment: \$200
Offering Minimum: \$10,000
Offering Maximum: \$400,000

Terms

Offering Type: Debt/Equity
Security: Convertible Notes
Price per Note: \$1.00
Minimum Number of Notes Offered: 10,000
Maximum Number of Notes Offered: 400,000
Pre-Money Valuation: \$1,539,394

SEC FILINGS

DURING THE TEST THE WATERS PHASE OF THIS REG CF OFFERING, NO MONEY OR OTHER CONSIDERATION IS BEING SOLICITED, AND IF SENT IN RESPONSE, WILL NOT BE ACCEPTED. NO OFFER TO BUY THE SECURITIES CAN BE ACCEPTED AND NO PART OF THE PURCHASE PRICE CAN BE RECEIVED UNTIL THE OFFERING STATEMENT IS FILED AND ONLY THROUGH AN INTERMEDIARY'S PLATFORM. AN INDICATION OF INTEREST INVOLVES NO OBLIGATION OR COMMITMENT OF ANY KIND. RESERVING SECURITIES IS SIMPLY AN INDICATION OF INTEREST.

Risks

A crowdfunding investment involves risk. You should not invest any funds in this offering unless you can afford to lose your entire investment. In making an investment decision, investors must rely on their own examination of the issuer and the terms of the offering, including the merits and risks involved. These securities have not been recommended or approved by any federal or state securities commission or regulatory authority. Furthermore, these authorities have not passed upon the accuracy or adequacy of this document. The U.S. Securities and Exchange Commission does not pass upon the merits of any securities offered or the terms of the offering, nor does it pass upon the accuracy or completeness of any offering document or literature. These securities are offered under an exemption from registration; however, the U.S. Securities and Exchange Commission has not made an independent determination that these securities are exempt from registration.



© TycoonInvest 2020-2021. All rights reserved.

For Companies

- Raise Capital
- Why TycoonInvest
- The Process for Companies
- Company FAQ
- Investment Crowdfunding Basics

For Investors

- Invest
- The Process for Investors
- Investor FAQ
- Investor Disclosures
- Investment Crowdfunding Basics

About

- Refer Businesses
- About Us
- Careers
- Terms of Use
- Privacy Policy
- Contact Us

IMPORTANT MESSAGE

INVESTORS MUST RELY ON THEIR OWN EXAMINATION OF THE ISSUER AND THE TERMS OF THE OFFERING, INCLUDING THE MERITS AND RISKS INVOLVED, WHEN MAKING AN INVESTMENT DECISION. INVESTMENTS ON TYCOONINVEST ARE SPECULATIVE, ILLIQUID, AND INVOLVE A HIGH DEGREE OF RISK, INCLUDING THE POSSIBLE LOSS OF YOUR ENTIRE INVESTMENT.

Investment opportunities that are posted and accessible through this website are Regulation Crowdfunding offerings (2003 Act Title III; Section 4(a)(6)), which are offered to non-accredited and accredited investors alike. These offerings are made through TycoonInvest Portal LLC (dba TycoonInvest), a funding portal registered with the US Securities and Exchange Commission (SEC), and a member of the Financial Industry Regulatory Authority (FINRA CRD#312166).

Accordingly, TycoonInvest Portal LLC does not offer investment advice or recommendations, solicit purchases, sales, or offers to buy the securities offered or displayed on its portal, compensate employees, agents, or other persons for such solicitation or based on the sale of securities displayed or referenced on its platform or portal, or hold, manage, possess, or otherwise handle investor funds or securities.

Any securities offered on this website have not been recommended or approved by any federal or state securities commission or regulatory authority. TycoonInvest and its affiliates do not provide any investment advice or recommendation and do not provide any legal or tax advice with respect to any securities. All securities listed on this site are being offered by, and all information included on this site is the responsibility of, the applicable issuer of such securities. TycoonInvest does not verify the adequacy, accuracy, or completeness of any information. Neither TycoonInvest nor any of its officers, directors, agents, and employees makes any warranty, express or implied, of any kind whatsoever related to the adequacy, accuracy, or completeness of any information on this site or the use of information on this site. See our general disclaimer here.

TYCOON INC. runs TycoonInvest.com and TycoonInvest.com, and is the parent company of TycoonInvest Portal LLC. TycoonInvest Portal LLC is a funding portal that operates sections of TycoonInvest.com and TycoonInvest.com where Regulation Crowdfunding offerings are made. TYCOON INC., the parent company, is not regulated as either a broker-dealer or funding portal and is not a member of FINRA.

By accessing this site and any pages on this site, you agree to be bound by our Terms of Use and Privacy Policy, as may be amended from time to time without notice or liability. Potential investors are strongly advised to consult their legal, tax, and financial advisors before investing. The securities offered on this site are not offered in jurisdictions where public solicitation for offerings is not permitted; it is solely your responsibility to comply with the laws and regulations of your country of residence.

Care2Care is currently in the TEST THE WATERS phase for Regulation Crowdfunding investments

CARE2CARE

Enabling delivery of affordable medications for healthcare plans and individuals



Portsmouth, NH
Services



The mission is to be the premier provider of internationally sourced affordable medications for healthcare plans and individuals. Care2Care International will be known as a brand that builds lasting relationships with customers and plan members, and consistently delivers exceptional value.

Terms

Debt / Equity	Conv. Notes
Offering Type	Security
\$1.00	\$200
Price per Note	Min. Reservation
\$1.54M	TTW
Pre-Money Valuation	Offering

RESERVE NOW

This Reg CF Test the Waters offering is made available through TycoonInvest Portal LLC

Reserving securities is simply an indication of interest that involves no obligation or commitment of any kind.

- Opportunity
- Offering Terms
- Updates
- Q&A

Updates

Follow Care2Care to be notified of any future updates!



© TycoonInvest 2020-2021. All rights reserved.

For Companies

- Raise Capital
- Why TycoonInvest
- The Process for Companies
- Company FAQ
- Investment Crowdfunding Basics

For Investors

- Invest
- The Process for Investors
- Investor FAQ
- Investor Disclosures
- Investment Crowdfunding Basics

About

- Refer Businesses
- About Us
- Careers
- Terms of Use
- Privacy Policy
- Contact Us

IMPORTANT MESSAGE

INVESTORS MUST RELY ON THEIR OWN EXAMINATION OF THE ISSUER AND THE TERMS OF THE OFFERING, INCLUDING THE MERITS AND RISKS INVOLVED, WHEN MAKING AN INVESTMENT DECISION. INVESTMENTS ON TYCOONINVEST ARE SPECULATIVE, ILLIQUID, AND INVOLVE A HIGH DEGREE OF RISK, INCLUDING THE POSSIBLE LOSS OF YOUR ENTIRE INVESTMENT.

Investment opportunities that are posted and accessible through this website are Regulation Crowdfunding offerings (JOBS Act Title III; Section 4(a)(6)), which are offered to non-accredited and accredited investors alike. These offerings are made through TycoonInvest Portal LLC (dba TycoonInvest), a funding portal registered with the US Securities and Exchange Commission (SEC), and a member of the Financial Industry Regulatory Authority (FINRA CRD#310166).

Accordingly, TycoonInvest Portal LLC does not offer investment advice or recommendations; solicit purchases, sales, or offers to buy the securities offered or displayed on its portal; compensate employees, agents, or other persons for such solicitation or based on the sale of securities displayed or referenced on its platform or portal; or hold, manage, possess, or otherwise handle investor funds or securities.

Any securities offered on this website have not been recommended or approved by any federal or state securities commission or regulatory authority. TycoonInvest and its affiliates do not provide any investment advice or recommendation and do not provide any legal or tax advice with respect to any securities. All securities listed on this site are being offered by, and all information included on this site is the responsibility of, the applicable issuer of such securities. TycoonInvest does not verify the adequacy, accuracy, or completeness of any information. Neither TycoonInvest nor any of its officers, directors, agents, and employees makes any warranty, express or implied, of any kind whatsoever related to the adequacy, accuracy, or completeness of any information on this site or the use of information on this site. See our general disclaimer here.

TYCOONO INC. runs TycoonInvest.com and TycoonInvest.com, and is the parent company of TycoonInvest Portal LLC. TycoonInvest Portal LLC is a funding portal that operates sections of TycoonInvest.com and TycoonInvest.com where Regulation Crowdfunding offerings are made. TYCOONO INC., the parent company, is not regulated as either a broker-dealer or funding portal and is not a member of FINRA.

By accessing this site and any pages on this site, you agree to be bound by our Terms of Use and Privacy Policy, as may be amended from time to time without notice or liability. Potential investors are strongly advised to consult their legal, tax, and financial advisors before investing. The securities offered on this site are not offered in jurisdictions where public solicitation for offerings is not permitted; it is solely your responsibility to comply with the laws and regulations of your country of residence.

Care2Care is currently in the TEST THE WATERS phase for Regulation Crowdfunding investments

CARE2CARE

Enabling delivery of affordable medications for healthcare plans and individuals



Portsmouth, NH
Services

The mission is to be the premier provider of internationally sourced affordable medications for healthcare plans and individuals. Care2Care International will be known as a brand that builds lasting relationships with customers and plan members, and consistently delivers exceptional value.

Terms

Debt / Equity	Conv. Notes
Offering Type	Security
\$1.00	\$200
Price per Note	Min. Reservation
\$1.54M	TTW
Pre-Money Valuation	Offering

RESERVE NOW

This Reg CF Test the Waters offering is made available through TycoonInvest Portal LLC

Reserving securities is simply an indication of interest that involves no obligation or commitment of any kind.

Opportunity

Offering Terms

Updates

Q&A

Review for Care2Care

Posted by COMPANY - Welcome to the Care2Care Q&A Section. Ask your questions to the company here, and a company representative will answer them.

Leave a Reply

You must be [logged in](#) to post a comment.



© TycoonInvest 2020-2021. All rights reserved.

For Companies

- Raise Capital
- Why TycoonInvest
- The Process for Companies
- Company FAQ
- Investment Crowdfunding Basics

For Investors

- Invest
- The Process for Investors
- Investor FAQ
- Investor Disclosures
- Investment Crowdfunding Basics

About

- Refer Businesses
- About Us
- Careers
- Terms of Use
- Privacy Policy
- Contact Us

IMPORTANT MESSAGE

INVESTORS MUST RELY ON THEIR OWN EXAMINATION OF THE ISSUER AND THE TERMS OF THE OFFERING, INCLUDING THE MERITS AND RISKS INVOLVED, WHEN MAKING AN INVESTMENT DECISION. INVESTMENTS ON TYCOONINVEST ARE SPECULATIVE, ILLIQUID, AND INVOLVE A HIGH DEGREE OF RISK, INCLUDING THE POSSIBLE LOSS OF YOUR ENTIRE INVESTMENT.

Investment opportunities that are posted and accessible through this website are Regulation Crowdfunding offerings (JOBS Act Title III; Section 4(a)(6)), which are offered to non-accredited and accredited investors alike. These offerings are made through TycoonInvest Portal LLC (dba TycoonInvest), a funding portal registered with the US Securities and Exchange Commission (SEC), and a member of the Financial Industry Regulatory Authority (FINRA CRD#310166).

Accordingly, TycoonInvest Portal LLC does not offer investment advice or recommendations; solicit purchases, sales, or offers to buy the securities offered or displayed on its portal; compensate employees, agents, or other persons for such solicitation or based on the sale of securities displayed or referenced on its platform or portal; or hold, manage, possess, or otherwise handle investor funds or securities.

Any securities offered on this website have not been recommended or approved by any federal or state securities commission or regulatory authority. TycoonInvest and its affiliates do not provide any investment advice or recommendation and do not provide any legal or tax advice with respect to any securities. All securities listed on this site are being offered by, and all information included on this site is the responsibility of, the applicable issuer of such securities. TycoonInvest does not verify the adequacy, accuracy, or completeness of any information. Neither TycoonInvest nor any of its officers, directors, agents, and employees makes any warranty, express or implied, of any kind whatsoever related to the adequacy, accuracy, or completeness of any information on this site or the use of information on this site. See our general disclaimer here.

TYCOON INC. runs TycoonInvest.com and TycoonInvest.com, and is the parent company of TycoonInvest Portal LLC. TycoonInvest Portal LLC is a funding portal that operates sections of TycoonInvest.com and TycoonInvest.com where Regulation Crowdfunding offerings are made. TYCOON INC., the parent company, is not regulated as either a broker-dealer or funding portal and is not a member of FINRA.

By accessing this site and any pages on this site, you agree to be bound by our (Terms of Use) and (Privacy Policy), as may be amended from time to time without notice or liability. Potential investors are strongly advised to consult their legal, tax, and financial advisors before investing. The securities offered on this site are not offered in jurisdictions where public solicitation for offerings is not permitted; it is solely your responsibility to comply with the laws and regulations of your country of residence.

TITLE	Care2Care_Offering_20210722_Full
FILE NAME	Care2Care_Offering_20210722_Full.pdf
DOCUMENT ID	2a82b2148c0553b93308adf015c293c29fd25fd6
AUDIT TRAIL DATE FORMAT	MM / DD / YYYY
STATUS	● Completed

Document History



SENT

07 / 22 / 2021

07:29:10 UTC

Sent for signature to Andre Wencker (andre.wencker@care2care.fr) and Pascal Orliac (pascal@care2caremedicaltravel.com) from compliance@tycooninvest.com
IP: 68.9.117.53



VIEWED

07 / 22 / 2021

07:41:20 UTC

Viewed by Andre Wencker (andre.wencker@care2care.fr)
IP: 92.148.251.189



SIGNED

07 / 22 / 2021

07:46:46 UTC

Signed by Andre Wencker (andre.wencker@care2care.fr)
IP: 92.148.251.189



VIEWED

07 / 22 / 2021

14:35:50 UTC

Viewed by Pascal Orliac (pascal@care2caremedicaltravel.com)
IP: 81.53.189.49



SIGNED

07 / 22 / 2021

14:37:42 UTC

Signed by Pascal Orliac (pascal@care2caremedicaltravel.com)
IP: 81.53.189.49



COMPLETED

07 / 22 / 2021

14:37:42 UTC

The document has been completed.